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Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) and the most common neurological disorders affecting young 
adults [1]. It was the neurologist Jean-Martin Charcot (1825-1893) who first scientifi-
cally described, documented, and named the disease process which we still call MS [2]. 
Despite the bulk of research that has been done, the exact cause of MS remains un-
known. The aetiology of MS is most likely multi-factorial and caused by a complex inter-
action of auto-immune, environmental, and multiple genetic factors [1]. Women are 
affected more often than men, with approximately three women to every man diag-
nosed. The global distribution of MS can be generalized as increasing with the distance 
north or south of the equator [1]. The disease affects 1 in 1000 persons in North Euro-
pean countries; while in (sub)tropical countries the prevalence is relatively low, affect-
ing only 0,2 to 0,3 in 1000 people. Approximately 16000 people suffer from MS in the 
Netherlands (www.atlasofms.org). 
 MS is a disease in which the immune system attacks the myelin sheath surrounding 
the axons of neurons in the CNS. Inflammation of myelin is associated with the forma-
tion of hard plaques (sclerosis) in the CNS that disrupts neural transmission and results 
in the loss of many functions of the body. Plaques may appear anywhere in the CNS, but 
there is a predilection for the optic nerves, corpus callosum, spinal cord, brainstem and 
cerebellum [1]. Although MS is generally considered a disease of the white matter, 
more recent research has shown that areas of demyelination coexist with diffuse axonal 
and neuronal degeneration [3, 4]. 
 MS is a disease with an unpredictable clinical course that can follow different pat-
terns [1]. When the disease course is characterized by periods of relapses and remis-
sions with either partial or absolute recovery, the disease is subtyped as relapsing re-
mitting MS (RRMS). These periods of relapses and remissions are called exacerbations. 
In between the exacerbations the disease is stable. Approximately 80% of the patients 
are diagnosed with RRMS at onset of the disease. In around 65% of the cases this dis-
ease type evolves into a more progressive type called secondary progressive MS 
(SPMS). In SPMS a period of exacerbations is followed by a progression of symptoms. A 
minority of about 20% is diagnosed with primary progressive MS (PPMS), a disease type 
in which a constant progression in symptoms is noticeable since onset of the disease. 
 The individual prognosis of MS patients is difficult to predict, but there are several 
factors that indicate an unfavourable prognosis, such as: an initially progressive course; 
motor, cerebellar, and sphincter involvement at onset; a high number of early relapses; 
a short inter-relapse interval; and early residual disability [5]. Consistent with the vari-
able disease course, also the clinical picture of MS is diverse, including both physical 
and neuropsychiatric symptoms. Frequent symptoms are visual problems (optic neuri-
tis, diplopia, nystagmus), loss of function or feeling in limbs, difficulties with coordina-
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tion and balance (ataxia), problems with speech (dysarthria), as well as bowel and blad-
der dysfunction. Also cognitive impairment, mood disorder, sexual dysfunction, and 
fatigue are frequent in MS [6-8]. 
 Although the availability of immunomodulatory and immunosuppressive drug 
treatment has ameliorated the perspective for a lot of MS patients, MS is still an incur-
able disease [9]. Besides pharmacological treatment focused on the pathophysiologic 
mechanisms of MS, multidisciplinary symptom management can also improve the qual-
ity of life of MS patients [7]. 
Fatigue in MS 
Up to 92% of patients with MS complain of fatigue and characterize it as one of the 
most common and troubling problems [10]. Usually, fatigue presents itself as a chronic 
symptom, but it may also precede or accompany MS exacerbations [11]. Fatigue is 
frequently the first symptom of MS [12] and it is even reported as the only symptom of 
an acute relapse [13]. Fatigue can severely affect the ability to perform activities of 
daily life and is a major reason for unemployment. Therefore, fatigue is associated with 
excess disability and a poor quality of life [12, 14-19]. 
 
The following case reports illustrate the clinical aspects of fatigue and its impact on 
daily functioning in two MS patients.  
Case 1 
Ms. A. is a single 29-year old woman with a three-year history of relapsing-remitting 
MS. Her first and second exacerbations presented with visual symptoms, limb weak-
ness, and severe fatigue. Besides some visual deficits due to an optic neuritis and mild 
feelings of fatigue after a whole working day, she recovered well and was able to work 
for six hours a day as a secretary at the university. For about five weeks, she has been 
experiencing a substantial increase of fatigue. Her energy level has deteriorated, she is 
sleeping a lot and she perceives great difficulties during mental activities, such as read-
ing. Because she is concerned about having a new exacerbation, she consults her neu-
rologist. He cannot discover any new neurological symptoms during neurological ex-
amination and also a new magnetic resonance imaging scan shows no changes. Despite 
the reassurance of the neurologist that the MS is under control, Ms. A. is very worried 
about her increasing fatigue and her cognitive complaints. Finally, the neurologist refers 
her to the department of medical psychology for clinical assessment and psychological 
support. 
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Case 2 
Mrs. B. is a married 43-year old woman who was diagnosed with primary progressive 
MS nine years ago. She is moderately disabled. Outside, she can only walk with the 
assistance of her husband, but at home she is mostly independent because of the un-
impaired function of her upper limbs. At every half-year visit to her neurologist she 
utters complaints of fatigue. Since a few months, the fatigue has become markedly 
aggravated and it is not possible anymore for her to run her household on her own. She 
has to ask for assistance from her husband more often, and outside she now has to use 
her electrical wheelchair. Mrs. B. feels very embarrassed and irritated about the in-
crease of her dependency. She has experienced a loss of appetite and has lost 6 pounds 
in weight in the last four months. Furthermore, she lacks interest, is slow in speech and 
has memory problems. Her husband describes her as always having been a very precise 
and nervous person, who is often distressed. He asks the neurologist for advice about 
handling his wife’s increased fatigue. 
 
Several questions that are important for clinical practice arise from these two cases: 
- What is MS-related fatigue and is it related to psychological factors? 
- Is cognitive functioning negatively affected by fatigue? 
- How disease specific is fatigue in MS? Is fatigue associated with disease-related 
factors and is the contribution of disease severity and psychological factors in MS 
different from that in patients with a non-neurological chronic auto-immune dis-
ease? 
- Are depression and negative affectivity risk factors for fatigue in MS? 
- Does worrying about fatigue increase MS-related fatigue and physical disability? 
 
These questions form the basis for the research described in this thesis. 
Aims, research questions, and outline of thesis 
Although fatigue is a common and troublesome symptom in MS, its pathogenesis is still 
poorly understood. Previous studies and reviews on its aetiology have largely focused 
on the biological underpinnings of fatigue in MS [11, 20-23], but until now the evidence 
for explanatory pathophysiological factors is at best conflicting. Effective pharmacologi-
cal treatments for MS-related fatigue are hardly available so far. Alternatively, a psycho-
logical approach may be helpful in providing further explanations. Insight into the im-
pact of psychological factors on fatigue in MS would be helpful in improving our overall 
understanding of MS-related fatigue. This in turn might be helpful when it comes to the 
development of interventions to treat those patients with this frequent and disabling 
symptom. 
C H A P T E R  1  
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The general aim of this thesis is to better understand the concept of MS-related fatigue 
from a psychological perspective. As such the focus is on identifying relevant psycho-
logical factors in explaining MS-related fatigue and their added value to biological fac-
tors such as disease severity and cerebral white matter lesions.  
 
The results described in this thesis are based on a review of the recent literature and on 
the data of two samples. We will answer the following research questions:  
 
1. What is MS-related fatigue and what is currently known about the contribution of 
psychological factors to fatigue in MS patients? 
In Chapter 2, we will start with a critical review that focuses on whether psychological 
factors can help to explain MS-related fatigue. We will begin by defining fatigue in MS 
and discussing how it is measured. Next, conceptual issues and the relationships be-
tween MS-related fatigue and respectively mood, anxiety, cognition, personality, and 
cognitive behavioural factors will be discussed. Finally, the implications for clinical prac-
tice and research will be presented. 
 
2. What is the impact of fatigue on subjective and objective cognitive functioning in MS 
patients? 
In Chapter 3, we will investigate the contribution of fatigue to both cognitive complaints 
and cognitive performance in MS patients. Fatigue will be operationalized with the help 
of self-reported measures of both physical and mental fatigue. A relatively extensive 
neuropsychological assessment battery will be used which includes a number of tasks 
that require effortful information processing. We hypothesize that fatigue, together 
with anxiety and depression, contributes to cognitive complaints. Furthermore, we 
expect to discover that fatigue is related to cognitive performance in neuropsychologi-
cal tests that require attention and executive functioning.  
 
3. Is mental fatigue a primary symptom of MS and associated with disease-related fac-
tors?  
In Chapter 4, we will focus on mental fatigue in MS and its disease specificity by com-
paring its levels and correlates with those of two control groups. The first group we will 
include is composed of healthy control participants. The second group is composed of 
patients with ulcerative colitis (UC), viz. an inflammatory bowel disease without known 
underlying cerebral pathology. Like MS, UC is a chronic, intermittent, and functionally 
disabling disease characterized by a lifetime risk of relapses and including this group will 
help us to control for non-specific aspects of chronic disease. Mental fatigue will be 
assessed as well subjectively as objectively. First of all, we will compare the levels of 
mental fatigue in the three groups of participants. Secondly, we will explore the asso-
ciations between mental fatigue and disease severity in both of the patient samples. 
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Finally, we will examine how mental fatigue is respectively associated to cerebral white 
matter lesion load measured by MRI (cWML) and to depressive complaints in all of the 
three groups. We expect to find that the levels of both subjective and objective assess-
ment of mental fatigue are higher in MS patients than those in both control groups. 
Furthermore, we hypothesize that in the case of all participants depressive complaints 
are related to subjective assessment of mental fatigue, whereas both cWML and dis-
ease severity are related to objective assessment of mental fatigue. 
 
4. How disease specific is MS-related fatigue? Is the contribution of disease severity, 
depression and negative affectivity different in MS patients from that in patients with a 
non-neurological chronic auto-immune disease? 
In Chapter 5, we will again examine the specificity of fatigue to MS by comparing MS 
patients with UC patients, but we will now focus on the impact of disease severity, 
depression, and negative affectivity on both subjective physical and mental fatigue. 
First, we will compare the levels of fatigue in both patient groups. Next, we will explore 
the relative contribution of disease severity, depression, and negative affectivity, to 
fatigue in MS patients and compare this to their contribution in the case of UC patients. 
Besides overall relevance in both patient samples, we expect to find that both disease 
severity and depression contribute more to fatigue in MS patients than they do to fa-
tigue in UC patients. We also expect to find that negative affectivity contributes less to 
fatigue levels in MS patients than to fatigue levels in UC patients. 
 
5. Is MS-related fatigue a consequence of the disease severity or does the negative in-
terpretation of fatigue perpetuate or aggravate the experience of fatigue? 
In Chapter 6, we will investigate the role of catastrophic (mis)interpretations of fatigue 
on fatigue and physical disability in MS patients. We will compare a cognitive behav-
ioural model with a traditional biomedical model by using structural equation modelling 
(SEM). The hypothesis based on the cognitive behavioural model is that patients who 
catastrophically interpret their fatigue also report more fatigue-related fear and avoid-
ance behaviour, and hence are more physically disabled and depressed. In contrast, the 
biomedical model assigns a more prominent role to disease severity in the case of fa-
tigue as well as depression. Hence, it considers catastrophizing about fatigue, and fa-
tigue-related fear and avoidance behaviour, as consequences rather than as precursors 
of physical disability. By applying SEM, we will test whether structural relationships 
between substantively meaningful variables show a better fit with either of the theo-
retical models. In line with evidence in other populations, we expect to find that the 
overall test of the cognitive behavioural model will show a better fit than that of the 
traditional biomedical model. 
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Finally, in Chapter 7 (Concluding remarks) the main findings will be summarized, dis-
cussed, and placed into perspective within the context of this thesis and the recent 
literature. We will discuss the methodological issues related to the studies and make 
recommendations for future research and clinical practice.  
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Abstract 
Fatigue is a frequent and disabling symptom in patients with multiple sclerosis (MS), but 
it is difficult to define and measure. Today, MS-related fatigue is not fully understood 
and the evidence related to explanatory pathophysiological factors is conflicting. Here, 
we evaluate whether psychological factors can help to explain MS-related fatigue. In-
sight into the possible underlying psychological mechanisms might help us to develop 
adequate psychological interventions and to improve the overall management of fa-
tigue. Conceptual issues and the relationships between MS-related fatigue and mood, 
anxiety, cognition, personality, and cognitive behavioural factors are discussed and the 
implications for clinical practice and research are presented. 
 
T H E  P S Y C H O L O G Y  O F  F A T I G U E  I N  M S  
 19 
Introduction 
Multiple sclerosis (MS) is a chronic and unpredictable inflammatory demyelinating 
disease of the central nervous system (CNS), and it is one of the most common neuro-
logical disorders affecting young adults [1]. Consistent with variations in the distribution 
of pathological white matter lesions in the CNS, the clinical symptoms of MS are diverse 
and can include visual problems, loss of function or feeling in limbs, bowel and bladder 
incontinence, and loss of balance. In addition, non-focal neurological symptoms, such as 
cognitive and behavioural problems, are frequently reported [2]. Up to 92% of patients 
with MS complain of fatigue and characterize it as one of the most common and trou-
bling problems [3]. Fatigue can severely affect the ability to perform activities of daily 
life and is a major reason for unemployment. Therefore, fatigue is related to disability 
and poor quality of life [4-10]. 
 Although fatigue is a common and troublesome symptom, its pathogenesis is 
poorly understood. Studies on the aetiology of fatigue and reviews about this topic 
have largely focused on the biological factors [11-16]. If fatigue were directly related to 
the underlying pathophysiology of MS, and thus were a primary somatic manifestation 
of MS, then we would expect to see a significant relationship between fatigue and dis-
ease-related variables. A number of studies have investigated the relationship between 
fatigue and disease course, disease duration, and neurological impairment, yet no con-
sensus has been reached [13]. Furthermore, several studies failed to establish an asso-
ciation between MS-related fatigue and typical magnetic resonance imaging (MRI) 
markers of the disease, such as T2 lesion load, gadolinium-enhancing lesion activity, and 
brain atrophy [17-21]. Other studies found significant but small relationships using 
functional neuroimaging techniques [22-26]. Because fatigue often occurs during dis-
ease exacerbations and is also reported to be a side effect of disease-modifying medica-
tion, such as interferon-β, a relationship with auto-immune dysregulation has been 
suggested [14, 27]. However, the results of studies concerning the relationship between 
MS-related fatigue and pathophysiological mechanisms, including auto-immune and 
neuroendocrine dysregulation, autonomic system dysfunction, and peripheral muscular 
mechanisms, are contradictory [28-33] (see Kos et al. [13] for a review of the biological 
mechanisms of MS-related fatigue). 
 While one might expect to find a biological explanation for MS-related fatigue, 
none of the proposed pathophysiological mechanisms can fully explain MS-related 
fatigue. In this critical review, our aim is to evaluate the contribution of psychological 
factors in explaining fatigue in MS. In Iine with findings related to other somatic symp-
toms [34-37], it is possible that fatigue in MS is determined by psychological factors 
such as mood, anxiety, and cognitive impairment, which also are common sequelae in 
MS [38-40]. Furthermore, because it is known that the patients’ perception and inter-
pretation of their illness and the way they behave are important predictors of disability 
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[41], it follows that personality and cognitive behavioural factors could contribute to 
MS-related fatigue. Insight into the psychological correlates or mechanisms of fatigue 
might help us to develop adequate interventions and to improve its overall manage-
ment. 
 We begin by defining fatigue in MS and discussing how it is measured. Next, we 
focus on conceptual issues including the relationships between MS-related fatigue and 
mood, anxiety, and cognitive impairment, and the impact of both personality and cogni-
tive behavioural factors on MS-related fatigue. We conclude with remarks about the 
implications for clinical practice and future research. 
Search strategies 
In order to ensure that we presented a complete overview of the potential contribution 
of psychological factors to fatigue in MS, we identified relevant studies by searching on 
MEDLINE, Pubmed, PsycLIT, Cochrane databases, and by consulting references from 
relevant articles (until January 2008). The following searching terms were used: multi-
ple sclerosis, fatigue, tiredness, depression, anxiety, fear, mood, cognition, cognitive, 
neuropsychological, psychological, personality, coping, neuroticism, emotional instabil-
ity, negative affect(ivity), illness cognitions, beliefs, catastrophizing, cognitive be-
havio(u)ral, treatment. 
Definition and measurement of fatigue in MS 
In 1998, the Multiple Sclerosis Council for Clinical Practice Guidelines reached consen-
sus on the following definition of fatigue in MS [42] “a subjective lack of physical and/or 
mental energy that is perceived by the individual or caregiver to interfere with usual 
and desired activities.” This definition implies that fatigue is a subjective experience, 
based on a patient’s self-report, and refers to the perception of exhaustion - physically, 
mentally, or both. The Multiple Sclerosis Council for Clinical Practice Guidelines further 
differentiated between acute (newly occurring in the past 6 weeks) and chronic (lasting 
longer than 6 weeks) fatigue. 
 Chaurdhuri and Behan [43] proposed a distinction based on physiology, differenti-
ating between central and peripheral fatigue. Central fatigue, in contrast to neuromus-
cular or peripheral fatigue, represents a failure to complete physical and mental tasks 
that require self-motivation and internal cues in the absence of demonstrable cognitive 
failure or motor weakness. A feeling of constant exhaustion is a characteristic of central 
fatigue, which is typically seen in MS and might be related to lesions in pathways of 
arousal and attention, such as the reticular and limbic systems, and the basal ganglia 
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[44]. However, there is no direct evidence that this mechanism is relevant. Therefore, 
the distinction between central and peripheral fatigue remains hypothetical, and the 
definition of fatigue as suggested by the Multiple Sclerosis Council for Clinical Practice 
Guidelines remains [42]. 
 Although there are a wide variety of self-report measures for MS-related fatigue 
(see Christodoulou [45] for an overview), there remains no consensus about clinically 
relevant, reliable, and responsive outcome measures for fatigue in MS. Given the physi-
cal and mental aspects of MS-related fatigue, the measurement should be multidimen-
sional. Questionnaires such as the Multidimensional Fatigue Inventory [46] and the 
Checklist of Individual Strength [47] have been specifically designed to assess multiple 
aspects of fatigue, including physical and mental fatigue. 
 Even though the definition of MS-related fatigue implies self-report, the most obvi-
ous problem with self-report questionnaires is their retrospective bias. Several attempts 
have been made to assess fatigue objectively in order to overcome this limitation [48]. 
Physical fatigue is measured objectively by quantifying reductions in force, rate, or 
persistence of motor responses over time or following exposure to some event. Wors-
ening of performance on a mental task over time or after some defined cognitive effort 
could be used to quantify mental or cognitive fatigue, but there are few studies on this 
topic [49]. 
 So far, there is only consensus on the definition of MS-related fatigue. In order to 
facilitate future research it is important to reach consensus on the method of assess-
ment as well. MS-related fatigue has both physical and mental aspects that can be 
measured subjectively and objectively. Fatigue in MS, especially the mental aspects of 
it, is sometimes indistinguishable from feelings of depression, anxiety, or cognitive 
deficits. Therefore, the concept of fatigue needs to be further evaluated by exploring its 
possible relationship with depression and anxiety as well as with cognition. 
The relationship between fatigue and mood/anxiety in MS 
Depression is the most common psychiatric disorder in MS, and the estimated preva-
lence is high, ranging between 27% and 54% [39, 50-52]. The association between de-
pression and MS is widely recognized, and it is not surprising to find depressive symp-
toms in people coping with a chronic and highly variable disease course and an uncer-
tain prognosis [53]. Both psychological adjustment and pathophysiological mechanisms, 
including impaired mood-influencing biological systems, may underlie the frequency of 
depression in MS; however, the exact nature of this relationship is complex (see the 
reviews of Dalton and Heinrichs [53] and Siegert and Abernethy [54] for further depth 
and details of this topic). 
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Because fatigue is a common symptom of depression [55], we would expect to see a 
relationship between fatigue and depression in MS. However, this overlap represents 
the first methodological problem affecting the validity of assessments for both depres-
sion and fatigue. Self-report measures often share the component of fatigue which 
might explain the significant relationship between fatigue and depression that has been 
found in several studies [4, 56, 57]. Therefore, it has been recommended that fatigue 
items be removed from the depression questionnaires [58, 59] or that instruments 
designed for patients with chronic illnesses - such as the Hospital Anxiety and Depres-
sion Scale [60], in which no items assessing somatic symptoms are included - be used 
for assessment. Using this so-called exclusive approach, a recent cross-sectional study 
[61] of 739 MS patients reported that subjects with clinically significant depressive 
symptoms were much more likely to report disabling fatigue. The authors concluded 
that fatigue is highly sensitive and specific for clinically significant depressive symptoms, 
and they recommended screening for depression in MS patients who report disabling 
fatigue. 
 Most of the relevant studies have reported significant associations between de-
pression and fatigue [4, 8-10, 56, 57, 61-69], although most of these studies were cross-
sectional and there were great variations in the assessment methods used. Other stud-
ies have found no significant relationship [7, 47, 70-72], possibly due to small sample 
sizes [7, 71, 72]. 
 It is possible that sleep disturbances, also a symptom of depression, could account 
for the significant relationship between depression and fatigue. Sleep disturbances are 
common in patients with MS and are often related to the presence of fatigue and de-
pression [73-76]. Although the prevalence of sleep complaints is three times higher in 
patients with MS than in healthy controls [73], the evidence for disturbed sleep-wake 
rhythms in these patients is contradictory [77, 78]. In addition to depression, several 
other disease-related factors including pain and urinary symptoms, can influence the 
quality of sleep [74, 76]. It is possible that sleep disturbances mediate the relationship 
between depression and fatigue, but there is also evidence that sleep disturbances and 
depression are independent contributors to fatigue [67]. Strober and Arnett [67] found 
that both sleep disturbances and depression, together with disease severity, accounted 
for 43% of the variance, with sleep disturbances being the largest contributor. 
 While anxiety is a common affective symptom and frequently accompanies depres-
sion in MS patients [8, 38, 79-81], much less attention has been paid to its relationship 
with fatigue than to that of depression. In a recent study on mental and physical fatigue 
in MS [82], stress was an important correlate of mental fatigue only, while physical 
activity was an important correlate of physical fatigue, showing the importance of con-
ceptualizing fatigue as multidimensional. However, in the study by Skerret and Moss-
Morris [69], both depression and anxiety were significantly related to mental and physi-
cal fatigue. Other studies have found significant but modest associations between anxi-
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ety and MS-related fatigue [8, 70, 81]. Chwastiak et al. [61] did not find a relationship 
between fatigue and anxiety, but anxiety was assessed by asking a single question 
about the presence of an anxiety attack in the past month. 
 On the other hand, the association between both depression and anxiety with 
fatigue could be the result of the same underlying pathophysiological mechanism, such 
as the disruption of dopaminergic, histaminergic, and serotonergic pathways [83] and 
the dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis [84]. Moreover, sero-
tonin levels are influenced by the HPA axis, which in turn interacts with stress and fa-
tigue [85]. In addition, the paradigm of cytokine-induced sickness behaviour provides an 
explanatory mechanism [84, 86]. Proinflammatory cytokines that are produced in re-
sponse to infection induce the development of common symptoms of sickness, such as 
loss of appetite, sleepiness, withdrawal from normal social activities, and fatigue. This 
syndrome is defined as sickness behaviour and is now recognized as a motivational 
system that reorganizes the organism’s priorities to facilitate recovery from infection 
[86]. 
 Finally, the use of disease-modifying medication, such as interferon-β, could put 
MS patients at a risk for an increase in depressed mood, especially those with a history 
of depression [87-89], and this might indirectly cause fatigue. Therefore, it is important 
to describe patients’ characteristics in all studies that focus on fatigue and/or to specify 
inclusion criteria regarding medication use. 
 Unfortunately, the studies discussed here were cross-sectional and were not al-
ways based on an exclusive approach, which complicates interpretation and the draw-
ing of conclusions. In addition, longitudinal and randomized controlled studies are 
needed to infer causality and, in particular, to gain insight into the direction of influence 
(i.e. whether depression causes fatigue or visa versa). To the best of our knowledge, 
there are no available intervention studies that have focused on reduction of fatigue 
and its effect on depression in patients with MS. As of now, there are only two available 
intervention studies that have focused on the treatment of depression in MS, and both 
suggest that fatigue is caused by depression. In the one that investigated the efficacy of 
group therapy for treating depression in patients with MS, fatigue levels in MS patients 
declined slightly, whereas fatigue levels of control patients increased during the trial 
[90]. In the other intervention study, patients received either cognitive behavioural or 
supportive group therapy or sertraline, a selective serotonin reuptake inhibitor [91]. 
While this was an uncontrolled study, its findings also suggest that treatment for de-
pression is associated with reductions in the subjective severity of fatigue symptoms 
and that this relationship is due primarily to treatment-related changes in mood. In 
contrast, in their prospective study, Schreurs et al. [68] concluded that the presence of 
depression did not predict physical or mental fatigue after 1 year, nor was depression 
predicted by preceding fatigue experiences. 
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The relationship between fatigue and cognition in MS 
The methodological problem that occurs when studying the relationship between fa-
tigue and depression also occurs when studying the relationship between fatigue and 
cognition. Both subjective and objective mental or cognitive fatigue share a component 
of cognition, either as cognitive performance [49] or cognitive complaints, such as prob-
lems with attention and concentration [46, 47]. Therefore, when studying the relation-
ship between mental fatigue and cognition in MS, construct validity is an area of con-
cern. 
 Similar to depression, anxiety and fatigue, complaints of cognitive dysfunction are 
often reported by patients with MS [92], and 45%-65% of patients show measurable 
cognitive deficits [93, 94]. All cognitive domains can be impaired, but impairment of 
mental speed, cognitive flexibility, sustained attention, and memory retrieval, is quite 
common in MS [95]. Although MS patients typically report that their cognitive function-
ing is negatively affected by fatigue [7], there is limited evidence for this relationship. 
Only two cross-sectional studies have focused on the relationship between fatigue and 
cognitive complaints in MS [96, 97] and their results suggest that fatigue, together with 
emotional complaints and neurological impairment, contributes to cognitive com-
plaints. In addition, in other populations, noncognitive factors such as mood and anxi-
ety are important correlates of cognitive complaints [98-105]. 
 Furthermore, there is little evidence available regarding the impact of fatigue on 
cognitive performance based on neuropsychological assessments. Several studies did 
not find a relationship between subjective fatigue and cognitive performance [10, 106-
112]. In some studies, it is possible that no relationship was found because the neuro-
psychological assessment was reduced to a global screening battery with tasks that 
required minimal cognitive effort. Such screening batteries might not be appropriate for 
measuring how fatigue affects cognitive performance. In line with recent evidence in 
other populations [113-117], it is plausible that fatigue in MS is related to tasks that 
require sustained attention and executive control. Such tasks are often not assessed in 
MS patients because they are time consuming and can be enervating for this popula-
tion. Alternatively, effortful information-processing tasks, such as reaction tests, might 
depend on fine motor and visual functions, which can also produce noise in the studies.  
 To overcome the limitations of self-report measures, several techniques have been 
developed to objectively measure mental fatigue, also referred to as cognitive fatigue 
[49]. Cognitive fatigue can be conceptualized as a decrease in performance over a pro-
longed period, such as a working day, but can also be viewed as decreased performance 
during acute but sustained mental effort. 
 Although several attempts have been made, no studies have shown that worsening 
cognitive functioning over time is a correlate of objective or mental fatigue in MS. In 
most of the studies [108, 110, 118-120], a prolonged effort produced an increase in the 
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subjective experience of MS-related fatigue but this increase was not related to a de-
cline in cognitive performance. Jennekens-Schinkel et al. [109] examined reaction times 
before and after a 4-h neuropsychological evaluation in a group of MS patients and 
healthy controls. Although both reaction times and subjective fatigue increased in both 
groups, the magnitude of these changes did not differ between the groups. Other stud-
ies [107, 119, 121] have detected cognitive fatigue in MS, defined as a decrease in per-
formance on tasks for sustained attention. However, only one study [119] could distin-
guish between MS patients and healthy controls. Because of this lack of specificity and 
the problem of construct validity, the usefulness of objective measures of fatigue in 
clinical practice and research is dubious. Even if we can find measures that can sensi-
tively detect objective mental in MS patients, the experience of fatigue must be the 
starting point in daily clinical practice. 
The impact of personality factors 
There is substantial evidence that the personality trait of negative affectivity plays an 
important role in the experience and manifestations of chronic illness [34, 37, 122]. 
Negative affectivity, also called neuroticism or emotional instability, is one of the Big 
Five personality traits and is defined as a stable disposition to experience psychological 
distress across time and situations [41]. Individuals who score high on questionnaires 
that assess negative affectivity are likely to interpret bodily sensations in terms of ill-
ness, also referred to as the symptom-perception theory [41]. 
 There is some empirical evidence that increased levels of negative affectivity in 
healthy individuals, as well as in clinical populations (e.g. cancer), predispose to develop 
or maintain symptoms of fatigue [123-127]. Likewise, significant relationships between 
negative affectivity and fatigue have been found in patients with MS [128, 129]. 
 Besides negative affectivity, relationships between fatigue and other Big Five per-
sonality traits, including (high) conscientiousness and (low) extraversion, have been 
documented [127, 128]. However, the scientific evidence supporting relationships be-
tween these traits and fatigue is less clear-cut than that for negative affectivity [127]. 
Moreover, most of these findings must be interpreted with caution due to the cross-
sectional design of the studies, their lack of control groups, and potential confounding 
by affective co-morbidity. Because depression and anxiety are very common in MS, it is 
likely that these symptoms significantly influence the outcome of personality assess-
ments and in particular the level of negative affectivity [130]. Furthermore, MS, like all 
diseases of the CNS, may affect personality due to underlying pathophysiological 
changes in the frontal cerebral areas [131, 132]. 
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In conclusion, although there is some evidence that personality is related to fatigue in 
patients with MS, numerous methodological issues preclude drawing definite conclu-
sions at this time. 
A cognitive behavioural perspective 
As an extension of the symptom-perception theory [41], a cognitive behavioural model 
was recently proposed to explain fatigue and disability levels in patients with MS [69]. 
In the cognitive behavioural perspective on fatigue, emphasis is placed on illness cogni-
tions, referring to the way patients think about and interpret their fatigue experience. 
From this perspective, the individuals’ perception of what causes the symptoms, rather 
than the actual cause of the symptoms, determines their behaviour [69]. Although 
there is evidence that cognitive factors play a less significant role in physical and psy-
chosocial functioning in MS than in CFS [133], others report similar illness cognitions 
and behaviour profiles for both groups of patients [134, 135]. In line with studies in 
other populations [136, 137], negative thoughts like helplessness and somatic attribu-
tions have also been found to contribute to both fatigue and disability levels in MS 
patients [69, 138, 139]. If fatigue is attributed to a physical illness, patients are more 
likely to focus on their fatigue and to interpret the consequences of fatigue in a nega-
tive way, such as a sign of physiological damage [69]. 
 It is plausible that, as in the case of CFS and chronic pain [140-142], these negative 
illness cognitions in MS patients lead to inadequate responses to their fatigue. Although 
no causality has been proved, mental fatigue is strongly related to both avoidance rest-
ing behaviour and all-or-nothing behaviour [69]. This means that MS patients who re-
spond to their symptoms by either engaging in excessive rest or avoidance of activity or 
who push themselves hard when feeling well and then crash, are more fatigued and 
disabled [69]. 
 Although few randomized clinical trials (RCTs) have evaluated the effects of exer-
cise and cognitive behavioural therapy on fatigue in MS, there is some evidence that 
physical exercise and behavioural therapy can reduce fatigue [143-146]. One recent RCT 
found that a multidisciplinary fatigue management program improved the impact of 
fatigue [147]. The MS patients received energy saving methods and strategies, psycho-
social support, and physiotherapy during four sessions of 2h each. Surprisingly, the 
intervention group did not differ from the placebo group that received general informa-
tion about MS. It is possible that the physiotherapy was insufficiently intensive and its 
duration too short to elicit effects different from those resulting from regular daily 
exercise. Furthermore, it is interesting to note that the placebo intervention also influ-
enced the perceived impact of fatigue and patients’ self-efficacy [147]. Self-efficacy, the 
belief that one can effectively manage a challenging situation, is an important variable 
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in coping with an unpredictable chronic disease and also seems related to fatigue in MS 
[82]. 
 There is some evidence that exercise training and energy saving strategies reduce 
fatigue and increase self-efficacy [145, 146]. In patients with MS, the feeling that that 
they have little control can induce negative cognitions, promoting higher levels of de-
pression and fatigue. Additionally, exercise not only increases endurance and strength, 
but also improves sleep and reduces stress and depressive symptoms, thereby prevent-
ing a vicious circle [82, 144]. These positive effects of exercise contradict the general 
advice given to MS patients to avoid exercise [148]. Such advice is detrimental because 
it can contribute to the persistence of fatigue. 
 In summary, there is increasing evidence that illness cognitions and behaviour play 
significant roles in how patients with MS adjust to fatigue. While it is legitimate for 
patients with an unpredictable and incurable disabling disease to worry about their 
health, those patients who are depressed and score high on negative affectivity are 
especially at risk for negative cognitions [135]. Future research should focus on discern-
ing the cognitive behavioural mechanisms, and evaluating the efficacy of cognitive-
behavioural therapy for MS-related fatigue. 
Implications for clinical practice and future research 
Chronic fatigue has long been recognized as a major problem for MS patients and has to 
be seen as a multidimensional experience that can be related to such symptoms as 
depression, anxiety, and cognitive impairment. Future longitudinal studies and RCTs in 
which fatigue is conceptualized and operationalized multidimensionally, are needed in 
order to clarify the causal relationships between mood, anxiety, cognition, and MS-
related fatigue. These studies should (a) use adequate sample sizes; (b) specify the 
inclusion criteria adequately; (c) control for cointerventions and comorbidities; and (d) 
use clinically relevant, reliable, and responsive fatigue assessment tools as outcome 
measures, preferably based on international consent. High-quality studies might help to 
prevent confusion and provide answers to the very complex problem of fatigue in MS. 
 MS-related fatigue is probably multifactorial and it is likely that the relative contri-
bution of the different biological and psychological factors, varies in each MS patient 
who experiences fatigue. However, in clinical practice, MS patients are not helped by 
having their fatigue validated as an uncontrollable correlate of their disease. Psycho-
logical factors can contribute to fatigue reporting and play a role in its persistence. 
Patients and health care providers should be informed that the way patients perceive 
and cope with their fatigue could influence how they experience fatigue. Fatigued MS 
patients should be screened for depression and anxiety and, when present, these psy-
chiatric co-morbidities should be treated. Neuropsychological assessment is recom-
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mended when fatigued MS patients experience cognitive complaints. Furthermore, 
negative fatigue-related thoughts should be detected and adjusted. Physical activity 
and exercise should be encouraged in general. 
 Because of the lack of an effective pharmacotherapy for MS-related fatigue [149, 
150], future strategies for managing fatigue in MS patients should be extended to in-
clude psychological screening and treatment in addition to the regular medical therapy, 
occupational therapy, and physiotherapy. Future research integrating both biological 
and psychological mechanisms might answer the question of who is at risk for chronic 
fatigue and give rise to specific interventions that would help patients to achieve their 
goals in daily functioning. 
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Abstract 
Objective: To study the impact of physical and mental fatigue on cognitive complaints 
and cognitive performance in patients with multiple sclerosis (MS). 
Design: Cross-sectional study. 
Setting: An outpatient neurology clinic.  
Subjects: Eighty patients diagnosed with clinically definite MS. 
Measures: The subscales physical and mental fatigue of the Multidimensional Fatigue 
Inventory; the Hospital Anxiety and Depression Scale and the Cognitive Failure Ques-
tionnaire. Cognitive performance was assessed by an extensive neuropsychological test 
battery that included several tasks that required effortful information processing. 
Results: Both anxiety and depression and mental fatigue contributed to cognitive com-
plaints, explaining respectively about 9% and 39% of the total variance. The contribu-
tion of physical fatigue to cognitive complaints was not significant. Both physical and  
mental fatigue did not significantly contribute to cognitive performance in terms of 
mental speed, attention, memory and executive functioning. 
Conclusions: To refine interventions for those patients with cognitive complaints, we 
advise adding measurements of anxiety, depression and fatigue to neuropsychological 
assessment. Fatigue permits extensive neuropsychological assessment, which is needed 
to detect cognitive impairment in MS patients. 
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Introduction 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) with an unknown pathogenesis and an unpredictable course [1]. 
MS is one of the most common neurological disorders affecting young adults and the 
clinical picture is diverse, including physical and neuropsychiatric symptoms [2]. Both 
fatigue and cognitive dysfunction are very common and interfere with the overall qual-
ity of life in patients with MS [3-5]. Up to 92% of patients with MS complain of fatigue 
and characterize it as one of the most common and troubling problems [4]. While many 
MS patients report cognitive problems, 45% to 65% of patients show measurable cogni-
tive deficits [5], especially impairment of mental speed, cognitive flexibility, sustained 
attention, and memory retrieval [6]. MS patients frequently report that their cognitive 
functioning is negatively affected by the experience of fatigue [7-9]. Only two studies 
have examined the relationship between fatigue and subjective cognitive functioning or 
cognitive complaints in MS [10, 11]. Their results showed that fatigue, together with 
emotional complaints and neurological disability, contributed to cognitive complaints. 
 More is known about the relationship between fatigue and objective cognitive 
functioning or cognitive performance, based on neuropsychological assessments. Gen-
erally, there is a lack of a relationship between fatigue and cognitive performance in MS 
[12]. For instance, the level of fatigue in MS is not related to working memory, verbal 
and non-verbal memory, verbal fluency, executive functioning and attention [8, 9, 13-
19]. However, these studies do have serious drawbacks, such as small sample sizes that 
vary from 15 to 45 [8, 13-18], and the use of brief neuropsychological test batteries that 
require relatively little cognitive effort, such as the Brief Repeatable Battery of Neuro-
psychological Tests (BRBN) [9, 19]. The BRBN [19] is the most widely used instrument to 
assess cognitive functioning in MS patients and includes several short and sensitive 
tests to detect cognitive impairment in MS. However, such a screening battery might 
not be appropriate for measuring the effect of fatigue on cognitive performance. Given 
the evidence in other populations [20-23], a relationship between fatigue and cognitive 
performance is expected to be based on the rate of effort needed. To expect signifi-
cance, effortful test such as those for sustained attention and executive control should 
be included. Such tasks (e.g. the California Verbal Learning Task, the Wisconsin Card 
Sorting Test and vigilance tasks) are often excluded when testing MS patients because 
these are time-consuming and supposed to be too enervating for this population [24]. 
Sustained attention or vigilance is most often assessed with the Paced Auditory Serial 
Addition Test (PASAT) [25], which is a sensitive cognitive test that takes only a few min-
utes to administer. However, the PASAT is also a non-specific test that measures infor-
mation-processing speed, working memory and sustained attention. Performance could 
easily be negatively affected by mathematical ability and emotional factors, such as 
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anxiety and frustration [25]; therefore we should be careful when interpreting low 
scores as clinically significant. 
 The aim of the present study was to explore the impact of fatigue on both cognitive 
complaints and cognitive performance in patients with MS. We hypothesized that 1) 
fatigue, together with anxiety and depression, contribute to cognitive complaints, and 
that 2) fatigue is related to cognitive performance on neuropsychological tests that 
require attention and executive functioning.  
Methods 
Subjects 
Eighty outpatients (25 males and 55 females) diagnosed with clinically definite MS [26] 
were recruited from the Department of Neurology of the Maastricht University Medical 
Centre (MUMC), which has both a local and regional function. Patients were referred 
for a standardized neuropsychological evaluation, irrespective of whether they had 
cognitive complaints or not. Their mean age was 43.6 years (SD=9.1, range 24-60). Most 
of the MS patients (n=53) had a relapsing remitting disease course; 13 patients had a 
secondary progressive course; and 14 patients a primary progressive course. All of the 
patients lacked other health problems besides MS; they did not use corticosteroids; 
they had not experienced an exacerbation during the 4 weeks previous to the evalua-
tion; and they did not have severe visual, verbal, and/or motoric limitations that inter-
fered with (neuro)psychological testing. All of the patients were assessed at the MUMC. 
Basic demographic information was collected, including age, sex, and level of premorbid 
intelligence as measured with the Dutch version of the National Adult Reading Test 
[27]. Medical histories of all the patients (e.g. disease course, disease duration) were 
collected from the hospital database. The Expanded Disability Status Scale (EDSS) [35], 
which was assessed by an experienced neurologist familiar with EDSS recording (RH), 
provided a measure of neurological disability. The medical ethics committee of the 
MUMC approved the project and all patients gave their written informed consent. 
Measures 
Since in clinical practice MS-related fatigue is defined as a subjective experience with 
both physical and mental aspects [28], we quantified fatigue by using the physical and 
mental subscales of a multidimensional self-report questionnaire viz. the Multidimen-
sional Fatigue Inventory (MFI) [29]. Both subscales consist of four items with a 5-point 
response format with scores ranging from 4 to 20. The statements refer to aspects of 
fatigue during the past few days. Higher scores indicate more physical or mental fa-
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tigue. The MFI is repeatedly used in the case of patients with chronic (neurological) 
diseases [30-32], and the Dutch language version has shown good reliability and validity 
[29]. 
 The Hospital Anxiety and Depression Scale (HADS) [33] was used to assess com-
plaints of anxiety and depression. This instrument has been especially designed to 
screen physically ill patients for the assessment of anxiety and depression. The HADS 
does not include somatic symptoms. As such it excludes any overlap with somatic and 
affective symptoms. Both subscales consist of 7 items with scores ranging from 0 to 21. 
Higher scores indicate more complaints. Reliability and validity have been demon-
strated for the Dutch population [34]. 
 Cognitive complaints were assessed with the help of the Dutch version of the Cog-
nitive Failure Questionnaire (CFQ), which has good psychometric qualities [36, 37]. The 
CFQ consists of 25 items covering general daily cognitive mistakes, including failures in 
memory, attention, action and perception. The total score ranges from 25 to 125, and 
higher scores indicate a higher number of cognitive complaints. 
 To assess cognitive performance, a relatively extensive neuropsychological assess-
ment battery was used including a number of tasks requiring effortful information 
processing. Eleven psychometric tests were administered to all patients in a fixed order, 
taking about 120 minutes to complete. The oral version of the Letter Digit Substitution 
Test (LDST) [38] was administered to assess information-processing speed. The shifting 
score of the Concept Shifting Test (CST) (CSTc- (CSTa-CSTb)/2) corrected for motor 
speed [39] was used to measure mental flexibility and divided attention. The 40-item 
version of the Stroop Color Word Test (SCWT) [40, 41] was used to test response inhibi-
tion and selective attention. Sustained attention was measured by means of the Dauer 
Aufmerksamkeit Test (DAUF) of the Vienna Test System, which is a go-no-go computer 
task that has good psychometric qualities [42]. During this task, which lasts for ap-
proximately 25 minutes, 15 series of lines with five triangles are presented on a com-
puter screen and the participant has to press on a button every time two of the five 
triangles are pointing downwards. Participants are asked to respond as quickly as possi-
ble without making mistakes. The test measures reaction time as well as both accuracy 
(errors, omissions) and stability (standard deviation of the reaction time). The Digit 
Span subtask of the Wechsler Adult Intelligence Scale (WAIS) was administered to as-
sess working memory [43]. The total reproduction of the five learning trials and the 
uncued long-term delay of the Dutch version of the California Verbal Learning Task 
(CVLT) [44, 45] were used to evaluate verbal learning and memory. Visual memory was 
assessed with the help of the multiple choice version of the Benton Visual Retention 
Test (BVRT) [46]. Fluency tasks were administered to assess language production and 
strategy-driven retrieval from semantic memory. Semantic and phonemic fluency were 
respectively measured by means of the semantic fluency task of the Groninger Intelli-
gence Test [47], and the Controlled Oral Word Association Test (COWAT) [24]. The 
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computerized version of the Wisconsin Card Sorting Test (WCST) [48] and the Raven’s 
Standard Progressive Matrices (Raven’s SPM) [49] were used to measure executive 
functioning (cognitive flexibility and non-verbal abstract reasoning). 
Statistical analyses 
Data were checked for normality, outliers and extremes. Square root and logarithmic 
transformation were used for not normally distributed variables (skewness <-1 or >1) 
before parametric testing. To reduce the number of neuropsychological outcome vari-
ables, a principal components analysis (PCA) with oblimin rotation (Eigenvalue >1) was 
performed. This PCA suggested a four-factor solution accounting for about 70% of the 
variance. The four factors were called: 1) mental speed, 2) attention, 3) memory, and 4) 
executive functioning (See Table 1 for the neuropsychological tests and factor loadings). 
On the basis of these findings, four compound performance indices were calculated 
using the mean of the Z-scores of all the variables belonging to a specific factor. The 
signs of the test scores on all variables of both the “mental speed” and “attention” 
compound indices, and the variable perseverative errors of the WCST were inverted so 
that a negative score reflects below average performance and a positive score above 
average performance for all compound indices. 
 Pearson correlation coefficients were calculated to examine interrelationships 
between all independent and dependent variables. Next, hierarchical regression analy-
ses were conducted on both cognitive complaints and cognitive performance (i.e. the 
four compound performance indices). Age and premorbid intelligence were entered 
first as control variables. Next, disease severity, anxiety and depression, physical and 
mental fatigue were entered consecutively to determine the unique contribution of 
each variable. The assumptions of regression analysis including absence of multicollin-
earity (Variance Inflation Factors <2), homoscedasticity, normal distribution of the re-
siduals and absence of ‘influential cases’ (Cook’s distance <1) were checked for all mod-
els. P-values <0.05 were considered significant. For the regression analyses, the level of 
significance was set on p<0.01 after Bonferroni correction for multiple testing. Analyses 
were carried out using the SPSS version 15.0 for Windows. 
Results 
The demographic and clinical characteristics of the sample are presented in Table 1.  
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Table 1. Demographic and clinical characteristics of the sample (n=80) 
 Mean (SD) Range  
Sex (% male / % female)        31/ 69   
Age (in years) 43.6 (9.1) 24-60  
EDSS 3.6 (2.0) 0-7.5  
Disease duration (in years) 5.8 (6.4) 0.1-20.5  
NART IQ 102.6 (9.4) 76-130  
   Internal consistence (α) 
HADS 11.7 (7.3) 1-29 .87 
MFI - Physical fatigue 14.4 (3.8) 5-20  .80 
MFI - Mental fatigue 12.5 (4.5) 4-20  .89 
CFQ 39.2 (15.9) 8-81 .92 
    
Mental speed-index   Factor loadings 
LDST (number correct in 60 sec.) 37.0 (9.7) 14-71  .447 
SCWT- Card III (sec.) 41.6 (13.4) 21-101 -.420 
Verbal fluency: 
 - animals and professions (total number correct in 60 sec.) 
 
40.7 (10.0) 
 
20-66 
 
.927 
 - letters N, K, A ( total number correct in 60 sec.) 33.1 (9.6) 16-60  .641 
Attention-index    
CST-shifting score (sec.) 12.1 (10.2) -4-45  .771 
DAUF - reaction time (sec.) 0.96 (0.17) 0.65-1.51  .646 
DAUF - stability of reaction time (sec.) 0.24 (0.08) 0.11-0.48  .664 
Memory-index    
Digit span (number correct) 14.4 (3.4) 8-24  .443 
BVRT (number correct) 13.1 (1.5) 9-15  .591 
CVLT - total reproduction trial 1-5 52.4 (11.6) 24-71  .868 
CVLT- uncued long term delay  10.8 (3.5) 2-16  .981 
Executive functioning-index    
WCST (perseverative errors) 13.0 (10.7) 4-62 .731 
Raven’s SPM (number correct) 45.4 (8.0) 25-70 -.843 
EDSS= Expanded Disability Status Scale; NART IQ= National Adult Reading Test Intelligence Quotient; HADS= 
Hospital Anxiety and Depression Scale; MFI=Multidimensional Fatigue Inventory; CFQ= Cognitive Failure Ques-
tionnaire; LDST= Letter Digit Substitution Test; SCWT= Stroop Color-Word Test; COWAT= Controlled Oral Word 
Association Test; CST= Concept Shifting Test; DAUF= Dauer Aufmerksamkeit Test; BVRT= Benton Visual Reten-
tion Test; CVLT= California Verbal Learning Task; WCST= Wisconsin Card Sorting Test; Raven’s SPM= Raven’s 
Standard Progressive Matrices. 
 
Table 2 shows the zero-order correlations between all relevant variables. Anxiety and 
depression as well as physical and mental fatigue were significantly related to cognitive 
complaints (0.367<r< 0.721; p<0.01). With regard to cognitive performance, significance 
was found for the relationship between physical fatigue and performance on attention 
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(r=-0.310, p<0.01) and executive functioning (r=-0.249, p<0.05), respectively. Next, 
mental fatigue was significantly related to both performance on attention (r=-0.256, 
p<0.05) and memory (r=-0.285, p<0.05).  
 
Table 2. Pearson correlations of independent variables with cognitive complaints and cognitive performance 
indices (n=80) 
   CFQ Mental speed   Attention  Memory Executive 
functioning 
Age -0.056 -0.168 -0.258* -0.340** -0.255* 
NART IQ -0.155 0.255* 0.195 0.478** 0.278* 
EDSS -0.013 -0.132 -0.245* -0.233* -0.261* 
HADS 0.501** -0.047 -0.169 -0.086 -0.364** 
MFI-Physical fatigue 0.367** -0.001 -0.310** -0.181 -0.249* 
MFI-Mental fatigue 0.721** -0.101 -0.256* -0.285** -0.066 
CFQ= Cognitive Failure Questionnaire; NART IQ= National Adult Reading Test Intelligence Quotient; EDSS= 
Expanded Disability Status Scale; HADS= Hospital Anxiety and Depression Scale; MFI= Multidimensional Fatigue 
Inventory.  
*p<0.05; ** p<0.01 (2-tailed) 
 
The results of the final hierarchical regression analyses are presented in Table 3. All the 
assumptions of regression analysis were fulfilled for each model. Anxiety and depression, 
as well as mental fatigue significantly contributed to cognitive complaints, explaining 
about 9% and 39% of the total variance respectively. Because the measures of mental 
fatigue and cognitive complaints were highly correlated (r=0.72, p<0.01) and included 
some comparable items, (e.g. “When I am doing something, I can keep my thoughts on 
it”, “I can concentrate well”), an additional regression analysis predicting cognitive com-
plaints without the subscale mental fatigue of the MFI was conducted (data not shown). 
In this way we could ensure that there was no confounding by overlapping constructs. 
When mental fatigue was not entered in the model, anxiety and depression explained 
about 16% of the total variance of cognitive complaints (β=0.414, p<0.01). In this model, 
physical fatigue did not significantly contribute to cognitive complaints (β=0.239, p=0.05). 
 Both physical and mental fatigue did not significantly predict mental speed, attention, 
memory and executive functioning, after controlling for age, premorbid intelligence, neu-
rological disability, and anxiety and depression. Finally, anxiety and depression signifi-
cantly contributed to executive functioning, explaining about 14% of the total variance. 
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Table 3. Hierarchical linear regression models for variables predicting cognitive com-
plaints and cognitive performance (n=80) 
 CFQ Mental speed  Attention Memory Executive 
functioning 
     ß     ß      ß     ß      ß 
Age -0.009 -0.194 -0.211 -0.357* -0.261 
NART IQ 0.016 0.272 0.139 0.465* 0.286* 
EDSS -0.044 -0.134 -0.135 -0.166 -0.106 
HADS 0.234* -0.058 -0.021 0.010 -0.397* 
MFI-physical fatigue 0.062 0.208 -0.107 0.137 -0.031 
MFI-mental fatigue 0.603* -0.110 -0.195 -0.261 0.125 
R2 0.578 0.133 0.201 0.431 0.302 
CFQ= Cognitive Failure Questionnaire; NART IQ= National Adult Reading Test Intelligence Quotient; EDSS= 
Expanded Disability Status Scale; HADS= Hospital Anxiety and Depression Scale; MFI= Multidimensional Fatigue 
Inventory. 
*p<0.01 (2-tailed) 
Discussion 
The present study revealed that mental fatigue, together with anxiety and depression, 
accounted for a substantial part of the total variance of cognitive complaints. Physical 
fatigue did not contribute to cognitive complaints. Furthermore, both physical and 
mental fatigue did not contribute to cognitive performance in terms of mental speed, 
attention, memory and executive functioning.   
 The finding that cognitive complaints are determined by fatigue and emotional 
complaints is in accordance with previous work on both MS patients [10, 11] and other 
clinical populations [50-53]. Despite the definition of fatigue [28] and the recommenda-
tion to operationalize it multidimensionally [54], most of these studies used measures 
of general fatigue only. Our findings suggest that cognitive complaints are related to 
mental fatigue but not to physical fatigue. Given the overlap in items between mental 
fatigue and cognitive complaints (e.g. concentration problems), our multidimensional 
approach reveals a problem of construct validity as is also established by the high corre-
lation found. To adjust for overlapping items, we excluded the mental fatigue subscale 
in our post-hoc analysis. After that, only anxiety and depression - and not physical fa-
tigue - were contributing to cognitive complaints. 
 Although we used an extensive neuropsychological battery including effortful tests, 
both physical and mental fatigue did not contribute to cognitive performance. As such, 
inclusion of effortful tests did not result in significance and the degree of effort can not 
explain the absence of a relationship in earlier findings [9, 13, 14, 17, 19, 55].  Although 
MS patients frequently report that their cognitive functioning is negatively affected by 
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the experience of fatigue and it is generally recommended to avoid fatigue during 
neuropsychological assessment in order to maximize cognitive performance [24], there 
is a lack of evidence for a major influence of fatigue on cognitive performance in MS 
patients and several other clinical populations [12]. An explanation for the lack of a 
relationship between fatigue and cognitive performance might be the different underly-
ing mechanisms. It is likely that cognitive deficits are the result of the neurodegenera-
tive process of MS [5], whereas the experience of fatigue is related to psychological 
factors [54]. 
 In contrast to studies in clinical samples, findings in healthy participants suggest 
that fatigue results in a decrease of cognitive performance [20, 22, 23]. This contrast 
may imply that fatigue in healthy participants is different from that experienced by a 
clinical population such as MS patients [12]. For instance, healthy participants become 
only fatigued after physical or mental effort and benefit from rest-breaks and sleep, 
whereas MS patients experience fatigue even in rest and after sleep. 
 Several methodological issues have to be considered. Firstly, the cross-sectional 
design of the study makes it impossible to infer causality from the associations found. 
To infer causality, at least a randomized experimental or longitudinal design is needed, 
especially because of the fluctuating nature of the disease and the influence of varia-
tions in fatigue and cognitive performance over time [56]. Secondly, although we con-
trolled for neurological disability and we excluded patients with severe motor and visual 
impairment, visual vigilance tests depend on fine motor and visual function, which can 
be impaired in MS [24]. This might have influenced the reliability of this outcome vari-
able. Furthermore, we did not control for CNS-active medication, which is often used to 
treat MS-related symptoms such as spasticity, and is known to influence cognitive per-
formance [57]. 
 Assuming that the present results appear to be stable when the methodology is 
improved, several implications are apparent for clinical practice. Since anxiety, depres-
sion and fatigue have a significant impact on cognitive complaints, it is recommend to 
add their measures to neuropsychological assessment in patients with MS. In addition, 
the treatment of cognitive complaints should focus on these complaints rather than on 
cognition. Because fatigue in MS is not related to cognitive performance, it is permitted 
to use extensive neuropsychological assessement in fatigued patients with MS. Given 
the impact of cognitive impairment on daily life, and its heterogeneity in MS, extensive 
neuropsychological assessment is needed to detect even subtle cognitive dysfunction 
[3, 6, 58]. 
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Abstract 
Although mental fatigue is a common and disabling symptom of MS patients, its exact 
pathogenesis is still unclear. In order to study the disease specificity of mental fatigue in 
MS we compared a sample of 40 MS patients with 19 healthy controls (HC), and we also 
included 20 patients with another chronic auto-immune disease (UC) in order to control 
for non-specific aspects of chronic disease. To better understand MS-related mental 
fatigue, we used a subjective as wel as an objective measure of fatigue. Besides meas-
urement by self-report, mental fatigue was measured by a decreased performance on a 
task that required sustained mental effort. We explored the associations between both 
(subjective and objective) measures of mental fatigue and disease severity in both pa-
tient samples. Next, the associations between both measures of mental fatigue on the 
one hand and both cerebral white matter lesion load measured by MRI (cWML), and 
depressive complaints on the other hand, were investigated in all three groups. Our 
findings revealed that MS patients experienced more mental fatigue than both control 
groups, but the three groups did not differ with regard to the objective measure of 
mental fatigue. The total amount of cWML and disease severity did not correlate with 
the objective measure of mental fatigue. Depressive complaints were only correlated 
with subjective assessment of mental fatigue in the HC group and not in the MS and UC 
sample. In conclusion, our distinction between the subjective and objective assessment 
of mental fatigue did not help us to find an explanation in terms of either disease speci-
ficity or significant correlates of MS-related mental fatigue. 
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Introduction 
Fatigue is a common symptom in chronic disease [1], but fatigue in patients with multi-
ple sclerosis (MS) seems to be more severe and disabling than that in other somatic 
populations [2, 3]. Up to 92% of patients with MS experience fatigue [4] and although it 
is one of the most common and most disabling symptoms, its pathogenesis is still 
poorly understood [5]. Chaurdhuri and Behan [6] proposed that the most common type 
of fatigue in chronic disease is central fatigue. Central fatigue, in contrast to neuromus-
cular or peripheral fatigue, represents a failure to complete physical and mental tasks 
that require self-motivation and internal cues, in the absence of demonstrable cognitive 
failure or motor weakness. This concept of central fatigue implies a distinction between 
physical and mental fatigue. Recently increasing attention has been paid to mental 
fatigue in both healthy and clinical populations, since labour conditions have changed 
to a large extent from demanding physical effort to demanding mental effort. Hence, 
mental fatigue can severely affect the ability to perform activities of daily life and is a 
major reason for unemployment [7, 8]. 
 Mental fatigue can be defined and operationalized in two different ways [9]. Firstly, 
mental fatigue is often defined as a feeling or a subjective experience. Subjective men-
tal fatigue can be measured by self-report questionnaires such as the Multidimensional 
Fatigue Inventory [10]. Secondly, objective mental fatigue - also known as cognitive 
fatigue - is defined as a performance decrement and is measured by direct observation 
of behaviour. There have been several attempts to assess mental fatigue objectively in 
MS [11]. A recurrent approach is to assess mental fatigue as a decrease in performance 
on a task that required sustained mental effort [11-15]. For instance, Krupp & Elkins 
[13] demonstrated objective mental fatigue by a decline in performance over the 
course of a sustained working memory task. Compared to the first half of the task, MS 
patients showed a significant increase in reaction time during the second half of this 
working memory task, and this difference was significantly higher in patients than in 
healthy participants. Also Schwid et al. [15] found a decrease in performance during 
administration of the Paced Auditory Serial Addition Test (PASAT), a task for mental 
speed, working memory and sustained attention, which was indicative of objective 
mental fatigue. 
 There is evidence that subjective and objective measures of mental fatigue have 
different correlates. In general, subjective fatigue is related to psychosocial factors such 
as depression [16-18] rather than to disease-related variables, such as disease duration, 
disease severity as measured by the Expanded Disability Status Scale (EDSS) [16, 19-21], 
or magnetic resonance imaging (MRI) markers, such as lesion load, gadolinium-
enhancing lesion activity and brain atrophy [22-26]. Greim et al. [27] studied both sub-
jective and objective physical and mental fatigue in MS patients and healthy partici-
pants and found that depression affects the subjective experience of both physical and 
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mental fatigue, but not the objective measures of fatigue. In line with these findings, it 
is expected that objective mental fatigue, like cognitive impairment [28], is associated 
with disease-related variables, such as cerebral white matter lesion load (cWML) on 
MRI, and with disease severity as measured with the EDSS. 
 In the present study we focused on mental fatigue in MS and its disease specificity 
by comparing its levels and correlates with those of two control groups. First of all, we 
included healthy control participants (HC). Secondly, to control for non-specific aspects 
of chronic disease, we included patients with ulcerative colitis (UC), an inflammatory 
bowel disease without known underlying cerebral pathology. Both MS and UC are func-
tionally disabling auto-immune diseases, usually starting between the ages of 20 and 
40. Like MS, UC is a chronic and intermittent disease, characterized by a lifetime risk of 
relapses [29]. In contrast to other auto-immune disorders such as rheumatoid arthritis, 
UC patients are particularly appropriate as controls because pain is not a major symp-
tom in UC during remission. 
 We tested whether the levels of both subjective and objective fatigue were higher 
in MS than those in both HC and UC. Next, we explored the associations between both 
subjective and objective mental fatigue and disease severity in both patient samples. 
The associations between the fatigue measures and both cWML and depressive com-
plaints were explored in all three groups. We hypothesized that the levels of both sub-
jective and objective mental fatigue are higher in MS patients than those in UC and HC. 
Furthermore, it was hypothesized that for all participants, depressive complaints are 
related to subjective mental fatigue, whereas both cWML and disease severity are 
related to objective mental fatigue. 
Methods 
Participants 
Forty MS patients were recruited from the Department of Neurology of the Maastricht 
University Medical Centre (MUMC), which has both a local and regional function. The 
neurologist invited consecutive patients who showed up at the outpatients clinic, were 
aged 18 to 60 years and were diagnosed with clinically definite MS [30] to participate in 
the study. The Inflammatory Bowel Disease (IBD) – South Limburg database of the De-
partment of Gastroenterology of the MUMC was used to recruit the UC patients. UC 
patients diagnosed according to the Lennard-Jones criteria [31] were selected from the 
IBD database and were matched with the MS patients for sex and age. Partners and 
close family members of 20 MS patients, with no health problems, participated as HC. 
 To study fatigue in patients in whom the disease was not active and to avoid the 
effects of corticosteroid use, we excluded patients who had experienced an exacerba-
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tion within the previous 4 weeks. MS Patients with an EDSS >8 were excluded, because 
these patients generally have impaired function of the upper limbs that may interfere 
with psychological testing. Other exclusion criteria for all participants were: other (neu-
rological) diseases; dementia or severe cognitive dysfunction; visual, verbal and/or 
motoric limitations interfering with psychological testing. 
Measures 
Subjective mental fatigue was assessed by means of the subscale mental fatigue of the 
Multidimensional Fatigue Inventory (MFI) [10], that consists of four items with a five-
point response format (range 4-20). Higher scores indicate higher levels of mental fa-
tigue. The MFI is repeatedly used in patients with chronic (neurological) diseases [2, 32-
34] and the Dutch language version has shown good reliability and validity [10]. In this 
study Cronbach’s alphas were respectively .90 for the MS sample, .85 for the UC sample 
and finally .86 for the HC sample. 
 Objective mental fatigue was measured by means of the Dauer Aufmerksamkeit 
test (DAUF) of the Vienna Test System [35]. The DAUF takes approximately 25 minutes 
and it is a computer task designed to assess sustained attention which has good psy-
chometric qualities [35]. During this task 15 series of lines with five triangles are pre-
sented on a computer screen and the participant has to press a button every time two 
of the five triangles are pointing downwards. Participants are asked to respond as 
quickly as possible without making mistakes. The task measures reaction time as well as 
both accuracy (errors, omissions) and stability (standard deviation of the reaction time). 
To ensure understanding of the task and to prevent practice effects, all participants had 
to complete practice items before starting the task. Objective mental fatigue was calcu-
lated by means of subtracting the mean reaction time of the last three series from that 
of the first three series. A positive outcome indicates mental fatigue. Before this calcu-
lation was made, we checked if there was a need to correct for the so-called speed-
accuracy trade-off [36]. Trading accuracy for speed results in fast but relatively inaccu-
rate performance, whereas the opposite strategy results in accurate but rather slow 
performance. In all three groups, correlations between reaction time and the error and 
omission rate, were significantly positively correlated. These findings suggest that the 
slowest participants are also the ones that are the least accurate; therefore, accuracy 
was not used as a covariate. 
 To measure cerebral white matter lesion load (cWML) all participants underwent a 
MRI of the brain according to a standardized MS protocol [37]. Because cerebral white 
matter lesions can appear without some form of cerebral or neurological pathology [38, 
39], also the UC patients and HC participants underwent a MRI of the brain. A 1.5 Tesla 
Phillips Gyroscan, with a dual echo spin-off sequence was used and 5 mm contiguous 
axial T1-, T2-weighted and fluid-attenuated inversion-recovery (FLAIR) images of each 
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subject were made. All the MRIs were analyzed on the same computer workstation 
using the semi-automated seed growing software package Show_Images, which has a 
good intra- and interobserver reliability [40, 41]. Lesions were marked and borders 
were set on each slice by one reader (F.B.) who was blinded to the clinical findings. 
Afterwards, the total cWML in volumes of mm3 was automatically quantified by the 
Show_Image software. 
 In both patient groups a disease-specific measure was used to assess disease sever-
ity. In the MS patients the EDSS was used [42]. A slightly modified version of The Colitis 
Activity Index (CAI) was used to measure disease severity in UC (range 0-18) [43]. This 
self-report questionnaire includes the number of daily liquid stools, the presence of 
nocturnal diarrhoea and the percentage of bowel movements with visible blood in the 
stool. Both the EDSS and the CAI are widely used as outcome measures for monitoring 
the disease course of respectively MS and UC patients, and higher scores indicate 
higher disease severity. 
 The subscale depression of the Hospital Anxiety and Depression Scale (HADS) [44] 
was used for measuring depressive complaints. This subscale, which consists of 7 items, 
has been especially designed to screen physically ill patients for depression. Higher 
scores indicate more complaints of depression (range 0-21). Reliability and validity are 
adequate for several clinical populations [45, 46]. In this study Cronbach’s alphas were 
respectively .81 for the MS sample, .82 for the UC sample, and .72 for the HC sample. 
Procedure 
All the participants were invited to come to the hospital for MRI scanning and to com-
plete the questionnaires and the computer task. Demographic information (sex and 
age) was collected and the level of premorbid intelligence was measured with the 
Dutch version of the National Adult Reading Test [47], in order to describe and compare 
the three groups of participants. The EDSS was assessed by one experienced neurologist 
familiar with EDSS recording. Medical histories of the MS and UC patients (disease 
course, disease duration) were collected from the hospital databases. Disease duration 
was defined as the interval between the day of the (clinically definite) diagnosis and 
evaluation. The medical ethics committee of the MUMC approved the project and each 
participant gave written informed consent. 
Data analyses 
All data were checked for missing values, normality, outliers and extremes. One HC was 
excluded because of an outlier regarding reaction time. Square root transformation was 
used for abnormally distributed variables before parametric testing. Because of the lack 
of variance in cWML in both control groups, this variable was not transformed. Because 
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of the different ranges of both of the disease severity measures (0-10 versus 0-18), the 
scores of the MS disease severity measure (EDSS) were linearly transformed to the 
range of the CAI (EDSS-score/10x18) to directly compare their means in both patient 
samples. Group differences with regard to the participants’ characteristics and self-
report measures were analyzed by means of chi-square analyses (sex), one-way ANOVA 
(comparing three groups), and independent sample Student t-tests (comparing two 
groups). Non-parametric statistics (Kruskal-Wallis test for the differences between 
three groups and Mann-Whitney-U tests for two groups) were used for the variable 
cWML. To compare the levels of fatigue in the three groups, separate general linear 
model (GLM) univariate ANOVAs were conducted with disease severity and depressive 
complaints as covariates. The assumption of homogeneity of variance was checked for 
all ANOVA models. Spearman rank correlations were conducted to examine the rela-
tionship between the independent variables (sex, age, premorbid intelligence, disease 
duration, disease severity, depressive complaints, cWML) and the dependent variables 
(subjective mental fatigue and objective mental fatigue) for the three groups of partici-
pants. P-values <0.05 were considered significant. Analyses were carried out using the 
SPSS version 15.0 for Windows. 
Results 
The sample included 40 MS patients, 20 UC patients, and 19 HC participants (see Table 
1 for demographic and clinical characteristics). Most of the MS patients (62.5%) had a 
relapsing remitting disease course, 22.5% had secondary progressive MS and 15% had 
primary progressive MS. The average EDSS score in the MS sample was 3.6 (SD=1.8, 
range 0-7.5) and the mean CAI in the UC sample was 3.8 (SD=2.2, range 1-9). The three 
groups did not differ with regard to sex, age, premorbid intelligence and disease dura-
tion, but MS patients showed a higher disease severity than UC patients. MS patients 
also reported higher levels of depressive complaints than both control groups. Both UC 
and HC reported comparable levels of depressive complaints (t=-0.237, p=0.814). MS 
patients had a higher cWML than both UC (Z=-4,854, p=0.000) and HC (Z=-4.818, 
p=0.000), whereas the cWML in the UC and HC group did not differ (Z=-0.770, p=0.441). 
 MS patients reported higher levels of subjective mental fatigue than both control 
groups, even after controlling for depression (F(1,37)=6.261, p=0.003). When we con-
trolled for both depression and disease severity, the differences between the two pa-
tient groups were still significant (F(1,58)=11.673, p=0.001). Both the UC group and the 
HC group reported the same levels of subjective mental fatigue (t (37)= 0.826, p=0.414). 
Although MS patients reacted slower and their deviation in reaction time was higher 
than that of both control groups, calculated scores of objective mental fatigue did not 
differ among the three groups of participants. 
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Table 1. Demographic and clinical characteristics of the participants (means and standard deviations) 
 Multiple sclerosis
     (n=40) 
Ulcerative colitis
     (n=20) 
Healthy controls
     (n=19) 
Significance test 
       (df) 
Sex (% men/ % women)     35 / 65     45 / 55     63 / 37 Χ2 (2)=4.14 
Age (years) 42.9 (8.9) 45.6 (7.9) 46.1 (9.4) F(2,76)=1.42 
NART IQ 102.7 (7.8) 104.1 (9.9) 103.2 (7.9) F(2,76)=0.17 
Disease severity1 6.4 (3.3) 3.8 (2.2) - t (58)= 2.79* 
Disease duration (years) 6.2 (6.8) 8.5 (7.0) - t (58)= -1.73 
HADS-Depression  6.1 (4.1) 3.4 (2.9) 3.6 (3.1) F(2,76)=5.18* 
cWML (mm3) 2982.0 (3052.1) 122.4 (268.0) 179.9 (573.9) Χ2(2)=36.71* 
MFI-mental fatigue 12.5 (4.5) 8.8 (3.4) 8.0 (4.1) F (2,76)=10.14* 
DAUF-reaction time (sec.)  0.95 (0.17) 0.77 (0.09) 0.85 (0.14) F(2,76)=11.05* 
DAUF-SD reaction time (sec.) 0.24 (0.07) 0.14 (0.04) 0.18 (0.06) F(2,76)=17.92* 
DAUF-objective mental fatigue (sec.) 0.07 (0.25) 0.10 (0.18) 0.13 (0.18) F(2,76)=0.52 
NART IQ= National Adult Reading Test Intelligence Quotient; HADS= Hospital Anxiety and Depression Scale; 
cWML= Cerebral white matter lesion load on MRI; MFI= Multidimensional Fatigue Inventory; DAUF =The Dauer 
Aufmerksamkeit Test. 1Because of the different range of both disease severity measures, the scores of the 
Expanded Disability Status Scale were linearly transformed into the range of the Colitis Activity Index (0-18) for 
reasons of comparison (see measures). * p<0.01. 
 
Table 2 shows the Spearman rank correlations of all independent variables and both 
subjective and objective mental fatigue in the three groups. Depression was correlated 
with subjective mental fatigue only in the case of the HC group (rho=0.507, p=0.027). 
No significant correlations were found between cWML and either fatigue measures. 
 
Table 2. Spearman rank correlations of independent variables and fatigue measures  
 Multiple sclerosis 
(n=40) 
Ulcerative colitis  
(n=20) 
Healthy controls 
(n=19) 
 Subjective 
mental 
fatigue 
Objective 
mental 
fatigue 
Subjective 
mental 
fatigue 
Objective 
mental 
fatigue 
Subjective 
mental 
fatigue 
Objective 
mental 
fatigue 
Sex  0.178 -0.132 -0.373  0.026 0.201 -0.100 
Age  0.046 -0.046 -0.176 -0.026 0.355  0.228 
Premorbid intelligence  0.082  0.251 -0.054 -0.365 0.328 -0.104 
Disease duration  0.095 -0.179  0.158 -0.487*   -    - 
Depression  0.244 -0.089  0.437 -0.064  0.507* -0.284 
Disease severity1 -0.301 -0.245 -0.156 -0.440   -    - 
cWML (mm3)2  0.206 -0.173  0.188 -0.064 -0.177 -0.024 
1Expanded Disability Status Scale in MS and Colitis Activity Index in UC; 2cerebral white matter lesion load on 
MRI. *p<0.05. 
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Discussion 
To improve our understanding of MS-related fatigue, the present study focused on the 
concept of mental fatigue. This involved the subjective experience as well as an objec-
tive measure representing an increase in reaction time during a cognitive vigilance task. 
Levels of both subjective and objective mental fatigue were compared to those of pa-
tients with another chronic disease viz. UC patients, and to those of a HC sample. We 
also explored associations between both of the fatigue measures and disease severity, 
cWML, and depressive complaints respectively. 
 In line with our first hypothesis, MS patients experienced more mental fatigue than 
both control groups. Contrary to our expectations, the three groups did not differ with 
regard to objective mental fatigue. It was also surprising to find that cWML and disease 
severity were not associated with objective mental fatigue in either the MS or the UC 
sample. Furthermore, depressive complaints were related to subjective mental fatigue in 
the HC group only and no relationship was found in either the MS or the UC sample. 
 The present results are in contrast to those of other studies on objective mental 
fatigue based on measures of information-processing speed and sustained attention 
[12, 13, 15]. This inconsistency could have several reasons. First of all, we did not assess 
the overall cognitive status of the participants and in particular the MS patients, which 
might be related to the performance on the cognitive vigilance task. For instance, Kujala 
et al. [14] did find evidence for objective mental fatigue with the help of a visual vigi-
lance task that lasted 15 minutes, if MS patients had mild cognitive impairment. Sec-
ondly, the use of different tests, varying in duration and effort, could explain the incon-
sistent findings. The intensity of the task rather than its duration might affect outcomes 
of objective mental fatigue [48]. It is possible that the sustained attention task selected 
in the present study, despite its 30-minute duration, required relatively little executive 
control of behaviour that might be necessary to induce mental fatigue. Bryant et al. [12] 
showed that the underlying performance strategy during the Paced Auditory Serial 
Addition Test (PASAT) appeared to be more sensitive to objective mental fatigue than 
the performance itself. Only the outcome variable that relied on executive functioning 
revealed a fatigue effect in MS patients compared to healthy controls. Also the finding 
in healthy participants that working for two hours on cognitively demanding tasks re-
sulted in a reduction of goal-directed attention and decreased performance on execu-
tive tasks, such as the Wisconsin Card Sorting Test [49, 50], suggests that operationali-
zation of objective mental fatigue should be in terms of executive control. 
 In accordance with the findings of Greim et al. [27], the present study did not reveal a 
relationship between depressive complaints and objective mental fatigue. Although an 
association was found between depressive complaints and subjective mental fatigue in 
the HC group, we could not demonstrate significance in either the MS or UC sample. This 
finding is in contrast to other studies [16-18, 27], which show a positive association be-
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tween depression and subjective mental fatigue in MS patients. Our findings seem to 
suggest that fatigue in healthy participants is different from that in chronic illness popula-
tions. Disease-specific variables may play a role in explaining fatigue in chronic illness, but 
the present data do not support this conclusion in terms of severity and cWML. 
 Our study is unique in comparing MS patients with UC patients. Whereas UC pa-
tients were selected because they suffer from a chronic auto-immune disease without 
obvious CNS involvement, recently there has been increasing evidence based on an 
increased frequency of cWML compared to age-matched healthy participants that UC 
may also manifest itself in the central nervous system [51]. Although cWML can appear 
without some form of cerebral or neurological pathology [38, 39], we cannot exclude 
CNS involvement in the control groups selected in the present study. Compared to the 
HC group, which exhibited cWML in 15% of the cases, 30% of the UC patients exhibited 
cWML. Nevertheless, the percentage of cWML in MS patients is 88 and this is signifi-
cantly higher without showing a relationship with objective mental fatigue. As such, 
CNS involvement based on cWML is not a prerequisite for objective mental fatigue, 
which might explain the lack of differences in the level of objective mental fatigue be-
tween all samples. However, our method to assess CNS involvement, viz. T2-weighted 
lesion load, may be an underestimation of the complexity of impaired brain functioning. 
Functional MRI (fMRI) is a relatively new and sensitive measure in detecting the subtle 
changes in brain functioning during cognitive performance and it has been proved to be 
a valuable tool to demonstrate mental fatigue in MS [52, 53]. Although fMRI is a sensi-
tive tool, it may be less specific and therefore its use is questionable [54]. 
 In conclusion, the concept of central fatigue and our operationalization of mental 
fatigue did not help us to find an explanation in terms of significant correlates of MS-
related mental fatigue. This brings us back to the problem of the unknown underlying 
pathogenesis of fatigue in MS. Although it has been suggested that central fatigue is the 
major cause of fatigue in chronic disease, it is questionable whether central fatigue 
explains the experience of fatigue in clinical populations [55]. Perhaps we should focus 
more on neuromuscular or peripheral fatigue rather than on central fatigue. Further-
more, in line with empirical evidence in other clinical populations, such as patients with 
chronic fatigue syndrome [56], and cancer survivors [57], future studies should focus on 
psychological factors, such as personality traits, fatigue-related beliefs and behaviour, 
rather than on specific disease-related variables. This is not to deny a biological origin of 
fatigue in MS, but rather a plea for an integrated bio-psychosocial approach that may 
open more therapeutic options. 
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Abstract 
Background: Fatigue is one of the most common and troubling symptoms of multiple 
sclerosis (MS) and more severe and disabling than fatigue in other somatic populations. 
Although fatigue seems MS specific, its pathogenesis is still poorly understood. 
Objective: To study the disease specificity of fatigue in MS by comparing its level, its 
physical and psychological correlates to those of patients with ulcerative colitis (UC), a 
peripheral chronic auto-immune disease. We focused on the relative contribution of 
disease severity, depression and negative affectivity to fatigue in both patient samples. 
Methods: A total of 88 MS and 76 UC patients were included in this cross-sectional 
study. Fatigue, depression and negative affectivity were assessed respectively with the 
physical and mental fatigue subscales of the Multidimensional Fatigue Inventory; the 
depression subscale of the Hospital Anxiety and Depression Scale; and the neuroticism 
subscale of the Dutch NEO Five-Factor Inventory. The Expanded Disability Status Scale 
and the Colitis Activity Index were used to measure disease severity in MS and UC pa-
tients respectively. 
Results: While levels of both physical and mental fatigue were significantly higher in MS 
patients than in UC patients, there were no group differences in the contribution of 
disease severity, depression and negative affectivity to both physical and mental fa-
tigue. 
Conclusion: Although levels of fatigue are higher for MS patients when compared with 
UC patients, the correlates of fatigue do not indicate MS specificity. As such our results 
support a trans-diagnostic approach to fatigue in MS. 
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Introduction 
Fatigue is one of the most common and disabling symptoms of multiple sclerosis (MS), 
but its aetiology is still poorly understood [1, 2]. Up to 92% of the patients with MS 
complain of fatigue and over two-thirds of patients characterize it as the most troubling 
symptom [3]. Fatigue in MS is more severe and disabling compared to fatigue in healthy 
controls and several other somatic populations [4-9]. Usually, fatigue in MS presents as 
a chronic symptom, but it may also precede or accompany exacerbations [10-12]. Fa-
tigue is frequently the presenting symptom at the time of diagnosis [5], and it is even 
reported as the only symptom of an acute relapse [13]. These findings suggest that 
fatigue is intrinsic to MS, but even though there is increasing evidence for the role of 
disease-related pathophysiological mechanisms in MS-related fatigue, these mecha-
nisms can only explain a small part of the variance [1, 2]. 
 Since fatigue in MS is defined as a subjective experience [14], psychological vari-
ables are expected also to contribute to MS-related fatigue. Moreover, fatigue in a 
chronic illness often co-occurs with negative affect [15]. Compared to other chronic 
illnesses, depression is more common in MS, and MS patients are especially at risk for 
fatigue [16-18]. There is also evidence that the personality trait negative affectivity, also 
called neuroticism or emotional instability, plays an important role in the experience of 
chronic symptoms, including fatigue [19]. A few studies [4, 7, 20, 21] have examined the 
impact of negative affectivity on fatigue in MS, and in two of these studies significant 
associations between negative affectivity and fatigue have been found [4, 20]. In the 
study by Penner et al. [7] the relationship between negative affectivity and fatigue 
disappeared after controlling for depression in both groups, which suggests that the 
effect of negative affectivity on fatigue is mediated by depression. 
 Fatigue is a common symptom in chronic diseases and it is a multidimensional 
phenomenon that may be caused by many non-specific disease-related factors [15]. 
While there have been many efforts to study fatigue in MS and the factors affecting it, 
most of the studies have focused on comparison with healthy controls or they did not 
even use a control group. In contrast, the present study compared fatigue in MS to that 
in patients with ulcerative colitis (UC), which was taken as an example of another 
chronic auto-immune disease. UC is an inflammatory bowel disease without obvious 
CNS involvement, but like MS it is a chronic, intermittent, and disabling disease, charac-
terized by a lifetime risk of relapses, that starts between the ages of 20 and 40 [22]. 
 To study the specificity of fatigue in MS, we first compared the levels of fatigue in 
both patient groups. Next, we explored the relative contribution of disease severity, 
depression and negative affectivity to fatigue in MS patients compared to UC patients. 
Besides overall relevance in both samples, we expected that both disease severity and 
depression contribute more to fatigue in MS patients than in UC patients; whereas we 
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expected negative affectivity to contribute less to fatigue levels in MS patients than in 
UC patients. 
Methods 
Patient samples 
Eighty-eight MS patients and 76 UC patients were included in this cross-sectional study, 
which was conducted in the period from July 2004 to December 2006. The MS patients 
were recruited from the Department of Neurology of the Maastricht University Medical 
Centre (MUMC, Maastricht, the Netherlands), which performs both a local and regional 
function. Consecutively referred patients who showed up at the outpatients clinic, were 
aged 18 to 60 years, and were diagnosed with clinically definite MS [23], were asked to 
participate in the study. The UC patients were selected with the help of the Inflamma-
tory Bowel Disease (IBD) South Limburg database of the Department of Gastroenterol-
ogy at the MUMC. UC patients who had been diagnosed using the Lennard-Jones crite-
ria [24] were selected from the IBD database and matched with the MS patients on the 
basis of sex and age. 
 In order to study fatigue in patients in whom the disease was not active, we ex-
cluded patients who had had an exacerbation within the past 4 weeks. In the case of 
MS patients an exacerbation was defined as a sudden onset or increase within 24 hours 
of a symptom that resolves fully or partially over the course of weeks and for which a 
neurologist was consulted. An exacerbation of UC was defined as a score of 10 or more 
on the Colitis Activity Index [25] (see measurements). MS patients with a Kurtzke Ex-
panded Disability Status Scale (EDSS) score >8 [26] were also excluded, because pa-
tients in this range of scores generally have impaired function of the upper limbs, which 
may interfere with psychological testing. Other exclusion criteria were: use of corticos-
teroids, somatic co-morbidity, dementia, or severe cognitive dysfunction and visual, 
verbal and/or motoric limitations that interfere with psychological testing. 
Measurements 
We used a multidimensional assessment approach, based on the physical and mental 
fatigue subscales of the Multidimensional Fatigue Inventory (MFI) [27]. Both of these 
subscales consist of four items with a 5-point response format with scores ranging from 
4 to 20. The statements refer to aspects of fatigue during the past few days. Higher 
scores indicate more physical or mental fatigue. The MFI is generally used in the case of 
patients with chronic (neurological) diseases [4, 28, 29], and the Dutch language version 
has shown good reliability and validity [27]. In this study Cronbach’s alphas of both 
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subscales were respectively .80 and .89 for the MS sample and .90 and .89 for the UC 
sample. 
 The Expanded Disability Status Scale (EDSS) [26], assessed by the patient’s own 
neurologist (RH), who is an experienced MS neurologist familiar with EDSS recording, 
provided a measure of disease severity in MS patients. The EDSS is divided into 8 func-
tioning systems (pyramidal, cerebellar, brainstem, mental, bowel and bladder, visual-
optic, sensory, and other). Impairment in each system is graded separately by means of 
neurological examination. EDSS-scores range from 0 to 10, with 0 being normal neuro-
logical examination and 10 being death due to MS. The Colitis Activity Index (CAI) was 
used to measure disease severity in the case of UC patients [25]. For practical reasons, 
one item of the CAI (i.e. abdominal tenderness assessed by a clinician) was not in-
cluded. We did use the other 7 items of the CAI, including the number of daily liquid 
stools; presence of nocturnal diarrhoea; occurrence of faecal incontinence; severity of 
abdominal pain; percentage of bowel movements with visible blood in the stool; per-
ceived general well being; and the use of anti-diarrhoeal medication. The total score of 
this version of the CAI ranges from 0 to18. Both the EDSS and CAI are widely used as an 
outcome measure for monitoring the disease course. Higher scores on both measures 
indicate a higher level of disease severity. 
 The depression subscale of the Hospital Anxiety and Depression Scale (HADS) [30] 
was used to assess depressive complaints. This instrument has been especially designed 
to screen physically ill patients for the assessment of anxiety and depression; it does 
not include somatic symptoms. By making use of this instrument, we could ensure that 
fatigue and depression were measured as separate entities. The subscale depression 
consists of 7 items (scores ranging from 0 to 21). Higher scores indicate more com-
plaints of depression. Reliability and validity are adequate for the Dutch population 
[31]. In this study Cronbach’s alphas were respectively .85 for the MS sample and .82 
for the UC sample. 
 Negative affectivity was assessed with the neuroticism subscale of the Dutch NEO 
Five-Factor Inventory (P-NEO-FFI), which is a reliable and valid personality question-
naire [32]. This subscale consists of 12 statements, rated on a 5-point scale and result-
ing in total dimension scores ranging from 12 to 70. Higher scores indicate higher levels 
of neuroticism. Internal consistency of the neuroticism subscale in this study was high 
with Cronbach’s alphas of .86 in the MS sample and .88 in the UC sample. 
Procedure 
All the participants were evaluated at the Department of Psychology of the MUMC, 
where they completed the questionnaires. General information necessary for the de-
scription and comparison of the two patient groups was collected. This included sex and 
age, as well as the level of premorbid intelligence, which was measured with the Dutch 
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version of the National Adult Reading Test [33]. Medical histories of the MS and UC 
patients (disease course, disease duration) were collected from the hospital databases. 
Disease duration was defined as the interval between the day of the (clinically definite) 
diagnosis and evaluation. UC patients completed the CAI at inclusion. For the MS pa-
tients, EDSS-scores were collected from the hospital database. If there was no recent 
(>3 months before inclusion) EDSS-score available, the treating neurologist was con-
sulted for reassessment. The medical ethics committee of the MUMC approved the 
project and each participant gave informed consent. 
Data analyses 
Based on the significant results obtained from a sample of 80 MS patients in a compa-
rable study [20], we assumed that the number of patients included in the present study 
was sufficient. Data were checked for missing values, normality, outliers and extremes. 
Square root transformation was used for abnormally distributed variables before para-
metric testing. Differences in characteristics between the MS and UC group and self-
report measures were analyzed by means of independent sample Student t-tests and 
chi-square analyses. Because of the different ranges of both of the disease severity 
measures (0-10 versus 0-18), the scores of the MS disease severity measure (EDSS) 
were linearly transformed to the range of the CAI (EDSS-score/10x18) in order to be 
able to directly compare the mean of disease severity in both patient samples. 
 Furthermore, Pearson correlation coefficients were calculated for both groups in 
order to examine interrelationships between independent variables (age, sex, disease 
duration, disease severity, depression, negative affectivity) and dependent variables 
(physical and mental fatigue). Fatigue levels in both patient groups were compared with 
the help of multiple-regression analyses that were conducted in the total sample using 
a forced entry method with physical and mental fatigue as outcome measures and age, 
sex, disease duration, disease severity, depression, negative affectivity and disease as 
independent variables. In order to assess the contribution of disease severity, depres-
sion and negative affectivity to fatigue in both patient groups, we conducted multiple 
regression analyses in the MS and UC sample separately. 
 Next, we tested the impact of disease as a moderator between respectively disease 
severity, depression and negative affectivity on the one hand, and physical and mental 
fatigue on the other. In line with the procedure specified by Baron and Kenny [34] in-
teraction terms were calculated (disease severity x disease, depression x disease, and 
negative affectivity x disease) and entered in a second step. Before computing the in-
teraction terms, all independent variables were centred (dichotomic variables) or trans-
formed into standardized values (continuous variables) to avoid artificially induced 
multicollinearity. Because of the disease specific measurement of disease severity, we 
calculated standardized scores for both patient groups separately. The assumptions of 
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regression analysis (absence of multicollinearity, homoscedasticy, normal distribution of 
the residuals, and absence of ‘influential cases’) were checked for all models. P-values 
<0.05 were considered significant. Analyses were carried out using the SPSS version 
15.0 for Windows. 
Results 
Demographic and clinical characteristics  
Table 1 shows the demographic and clinical characteristics of both patient groups. Most 
of the MS patients (66%) had a relapsing remitting disease course, 18% had secondary 
progressive MS, and 16% primary progressive MS. The average EDSS score was 3.5 
(SD=1.9, range 0-7.5). In the UC sample, the mean CAI was 3.5 (SD=2.1, range 0-9). 
Compared to the UC group, the MS had higher ratings on disease severity, but shorter 
disease duration. On average, the MS patients had higher scores on physical fatigue, 
mental fatigue, and depression than the UC patients. Levels of negative affectivity were 
equal in both patient groups. 
 
Table 1. Demographic and clinical characteristics (mean, (SD)) of both patient groups 
 Multiple sclerosis 
(n=88) 
Ulcerative colitis 
(n=76) 
Sex (% male / % female) 30/70 32/68 
Age in years 43.6 (9.0) 45.3 (8.8) 
Premorbid intelligence  102.0 (9.4) 103.1 (9.8) 
Disease severity1 6.4 (3.5) 3.5 (2.1)* 
Disease duration 5.7 (6.2) 10.1 (7.0)* 
Physical fatigue 14.4 (3.7) 11.1 (4.8)* 
Mental fatigue 12.3 (4.6) 9.7 (4.6)* 
Depression 5.6 (4.0) 4.0 (3.6)* 
Negative affectivity 32.0 (8.6) 31.0 (9.0) 
1Because of the different range of both disease severity measures, the scores of the MS disease severity meas-
ure (EDSS) were linearly transformed into the range of the CAI (0-18) for reasons of comparison.  
*p<0.01 (2-tailed) 
Zero-order relationships between all measures and fatigue  
The correlations between all independent variables and physical and mental fatigue in 
both patient groups are presented in Table 2. In both groups, disease severity was sig-
nificantly related to physical fatigue (MS: r= 0.387; p<0.01, UC: r= 0.641; p<0.01). Fur-
thermore, in the case of both MS and UC patients, negative affectivity was significantly 
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related to both physical (MS: r= 0.350, p<0.01, UC: r= 0.522; p<0.01) and mental fatigue 
(MS: r= 0.422; p<0.01, UC: r= 0.569; p<0.01). Also depression was significantly related 
to both physical (MS: r= 0.507, p<0.01, UC: r= 0.521; p<0.01) and mental fatigue (MS: 
r= 0.521; p<0.01, UC: r= 0.554; p<0.01) in both patient groups. 
 
Table 2. Pearson correlations of all measures with fatigue in both patient groups 
                Multiple sclerosis 
(n=88) 
Ulcerative colitis 
(n=76) 
 Physical fatigue Mental fatigue Physical fatigue Mental fatigue 
Sex -0.024 0.138 0.075 0.127 
Age 0.193 -0.019 0.151 0.018 
Disease duration 0.267* 0.078 0.231* 0.154 
Disease severity1 0.387** -0.039 0.641** 0.199 
Depression 0.507** 0.368** 0.521** 0.554** 
Negative affectivity 0.350**  0.422** 0.522** 0.569** 
1 Expanded Disability Status Scale in MS and Colitis Activity Index in UC 
*p<0.05; ** p<0.01 (2-tailed) 
Multiple-regression analyses predicting physical and mental fatigue 
As shown in Table 3, disease independently contributed to both physical fatigue            
(ß= -0.326; p<0.01) and mental fatigue (ß= -0.196; p<0.01). This supported our first 
hypothesis that MS patients report significantly higher levels of both physical and men-
tal fatigue compared to UC patients, also after controlling for negative affectivity, de-
pression, disease severity, disease duration, sex, and age.  
 
Table 3. Multiple-regression models predicting physical and mental fatigue in the total sample (n=164) 
               Physical fatigue 
                          ß 
          Mental fatigue 
                         ß 
Sex 0.029 0.129 
Age 0.027 0.032 
Disease duration 0.081 0.039 
Disease severity 0.332** 0.111 
Depression 0.279** 0.307** 
Negative affectivity 0.166* 0.321** 
Disease1 -0.326** -0.196** 
R2  0.501** 0.367** 
1multiple sclerosis= -1, ulcerative colitis= 1 
*p<0.05; **p<0.01 (2-tailed)  
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The contribution of disease severity, depression and negative affectivity to fatigue in 
both samples is shown in Table 4. In both the MS and UC sample, disease severity con-
tributed to physical fatigue, but not to mental fatigue, explaining respectively about 6% 
and 26% of the variance. Depression was the largest independent contributor to physi-
cal fatigue in the MS group, accounting for about 14% of the variance, whereas depres-
sion accounted for about 9% of the variance of mental fatigue. In the UC sample, de-
pression explained about 7% and 10% of the variance of respectively physical and men-
tal fatigue. In both the MS and UC patient groups, negative affectivity only contributed 
to mental fatigue and not to physical fatigue, explaining respectively about 7% and 12% 
of the variance. 
 To test whether the factor disease would have a moderating effect on the relation-
ships between disease severity, depression and negative affectivity on the one hand, 
and fatigue on the other hand, interaction terms were calculated and added to the 
second step (data not shown). The addition of these three interaction effects did not 
result in a significant increment of R2 above that associated with the main effect model 
for both physical and mental fatigue (F-change= 2.319, p=0.078; F-change= 0.337, 
p=0.799). These results mean that the contribution of disease severity, depression and 
negative affectivity to fatigue does not significantly differ between the patient groups. 
 
Table 4. Multiple-regression models predicting physical and mental fatigue in both patient groups  
 Multiple sclerosis 
(n=88) 
Ulcerative colitis 
(n=76) 
 Physical fatigue 
    ß 
Mental fatigue 
    ß 
Physical fatigue 
    ß 
Mental fatigue 
    ß 
Sex 0.098 0.234* -0.056 0.009 
Age 0.024 -0.024 0.024 -0.073 
Disease duration 0.144 0.060 0.072 0.036 
Disease severity1 0.215* -0.158 0.624** 0.481** 
Depression 0.407** 0.345** 0.252* 0.338** 
Negative affectivity 0.116 0.272* 0.176 0.393** 
R2 0.371** 0.285**  0.519** 0.399** 
1Expanded Disability Status Scale in MS and Colitis Activity Index in UC 
*p<0.05; **p<0.01 (2-tailed) 
Discussion 
The aim of the present study was to improve the understanding of fatigue in MS by 
comparing its level and correlates to those of UC patients, a comparable but peripheral 
auto-immune disease. The correlates referred to the relative contribution of disease 
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severity, depression and negative affectivity to both physical and mental fatigue. The 
levels of both physical and mental fatigue were significantly higher in MS than in UC, 
suggesting MS specificity. The correlates, however, did not differ between both sam-
ples, suggesting a lack of MS specificity. 
 Although several previous studies did not find any association between disease 
severity, as measured with the EDSS, and fatigue [35-38], our study revealed that dis-
ease severity was an independent contributor to physical fatigue only, which is in line 
with other findings [7]. Contrary to our expectations, the groups did not differ when it 
came to the contribution of disease severity to fatigue. Hence, both MS and UC patients 
experienced more fatigue with increasing disease severity. In line with related studies in 
MS, which also used the so-called exclusive approach of measuring depression [38, 39], 
depression explained a moderate amount of the variance of both physical and mental 
fatigue in both patient samples. Given the problem that fatigue is a symptom of depres-
sion, we used the HADS, which excludes somatic items to ensure that fatigue and de-
pression were measured as separate entities. This is often not the case in related stud-
ies [7, 40-42]. 
 Whereas it became clear that depression contributed to both physical and mental 
fatigue in both patient samples, negative affectivity contributed to only mental fatigue. 
Although we did find significant correlations between negative affectivity and both 
physical and mental fatigue, the associations with physical fatigue disappeared after 
controlling for sex, age, disease duration, disease severity and depression. Our findings 
are in contrast to the results of Penner et al. [7], who did not find a relationship be-
tween negative affectivity and either physical or mental fatigue after controlling for 
disease severity, as measured with the EDSS, and depression. Several factors can ex-
plain these contradictory results, including the use of different instruments to assess 
fatigue and depression. Penner et al. [7] revealed that MS patients had elevated levels 
of negative affectivity compared to the healthy controls, and assumed that the increase 
of negative affectivity is related to the MS disease itself. In our study, levels of negative 
affectivity were equal in both patient groups. This is in accordance with other results [4] 
suggesting that elevated levels of negative affectivity are a feature of chronic illness and 
as such are not specific for MS. Our results support the need for a multidimensional 
assessment of fatigue, at least in a physical and mental dimension, as well as the impor-
tance of controlling for depression as a confounder. 
 Comparison of the independent contributors of physical and mental fatigue in both 
MS and UC patients revealed that there were no significant differences between these 
two patient groups. Given the fact that both MS and UC are auto-immune diseases, 
these findings could lead to a new hypothesis that immune system dysregulation is 
related to fatigue. However, attempts to correlate MS-related fatigue with immune 
system activation, assessed by circulating levels of cytokines, have so far led to inconsis-
tent results [43, 44]. To examine the hypothesis that MS-related fatigue is caused by 
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ongoing inflammation, future studies should focus on fatigue during exacerbations 
instead of on chronic fatigue. 
 Several methodological limitations to this study need to be mentioned. Firstly, the 
representativeness and comparability of both patient samples can be a point of discus-
sion. The recruitment procedure of both patient samples was different and as a result 
there might be a selection bias interfering with the present results. Secondly, the cross-
sectional design of our study makes it impossible to infer causality from the associations 
found. To infer causality an experimental longitudinal design would be needed. Thirdly, 
it is possible that strong associations between self-reported variables, such as depres-
sion, negative affectivity and fatigue are the result of similar methods of measurement. 
Fourthly, the measurement of disease severity in both patient groups merits further 
consideration. Although both the EDSS and the CAI are widely used as outcome scales 
for monitoring the disease course of respectively MS and UC patients, both of these 
scales are partly subjective. An overall biomarker of disease activity may enhance com-
parability across groups, but as yet no such valid and reliable biomarker is available. 
 Our study is unique in comparing MS patients with patients with UC, i.e. an auto-
immune disease without obvious CNS involvement. Although the ideal control group is 
always a point of discussion, UC patients are especially appropriate as controls, because 
UC is also a chronic, intermittent, and disabling disease, that most often starts between 
the ages of 20 and 40 [22]. Furthermore, fatigue and depression are common symp-
toms in both MS and UC [29, 45, 46], and UC is not characterized by chronic pain such 
as rheumatoid arthritis. 
 To disentangle the complex aetiology of MS-related fatigue, future research may 
focus on comparison with other clinical samples that have fatigue as a symptom. If 
there is additional evidence for non-specificity of fatigue in MS, we should use a trans-
diagnostic approach to fatigue. Such an approach may help to develop specific interven-
tions and to improve the overall management of fatigue in MS patients. 
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Abstract  
Background: Although fatigue is one of the most common and disabling symptoms in 
patients with multiple sclerosis (MS), its pathogenesis is still poorly understood. In a 
biomedical approach, MS-related fatigue is assumed to be directly related to the sever-
ity of the disease; whereas in a cognitive behavioural approach it is assumed that fa-
tigue is worsened or perpetuated not by the severity of the disease or its associated 
symptoms, but by the interpretation of these symptoms. The aim of the current study 
was to compare the assumptions of a biomedical model with those of a cognitive be-
havioural one.  
Methods: A sample of 262 MS patients completed a battery of questionnaires assessing 
physical fatigue; catastrophizing about fatigue; fatigue-related fear and avoidance be-
haviour; depression; and physical disability. Disease severity was assessed by a neurolo-
gist using the Expanded Disability Status Scale. Structural equation modelling was ap-
plied to test both models. 
Results: Neither of the models showed adequate fit of our data, and the modification 
indices supported an integrated cognitive behavioural model, in which catastrophizing 
about fatigue was a key factor that mediated the relationship between fatigue and 
fatigue-related fear and avoidance behaviour. Disease severity did indirectly contribute 
to fatigue, through fatigue-related fear and avoidance behaviour as well as physical 
disability. Depression appeared to be a negative consequence of physical disability, and 
contributed directly to both fatigue as well as to the catastrophizing about fatigue. 
Conclusion: Although we did not perform cross-validation of the final model, it is clear 
that there are a number of relevant factors besides the severity of symptoms to be 
considered when trying to explain fatigue and physical disability in MS patients, viz.: 
catastrophizing about fatigue, and fatigue-related fear and avoidance behaviour, in 
combination with depression, also play an important role. Hence, the modification of 
catastrophic thoughts about fatigue may be a promising intervention method to help 
MS patients achieve their daily life goals. 
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Introduction 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system with an unknown pathogenesis and an unpredictable course. MS is 
considered to be one of the most common neurological disorders affecting young 
adults [1]. The clinical picture of MS is diverse, including physical and neuropsychiatric 
symptoms [2]. Up to 90% of patients with MS complain of fatigue [3]. Although fatigue 
is one of the most common and disabling symptoms in MS patients, its pathogenesis is 
still poorly understood [4, 5].  
 From a traditional biomedical perspective, MS-related fatigue is considered to be a 
primary symptom of MS that is directly related to the severity of the disease. Although 
there is some evidence for underlying pathophysiological mechanisms, including in-
flammation, demyelinisation, axonal loss and neuroendocrine dysregulation, these 
variables appear to explain only a small part of the variance of both MS-related fatigue 
and its disability [4, 5]. More recently, a cognitive behavioural approach has been pro-
posed which suggests that fatigue is not perpetuated or worsened by the severity of the 
disease or associated symptoms, but by the individual’s interpretation of these symp-
toms [6, 7]. Empirical evidence for such an approach has been found in cases of chronic 
fatigue syndrome [8-10], cancer survivors [11], and chronic pain [12, 13].  
 One of the key variables in recent cognitive behavioural approaches of symptom 
reporting is the way information is interpreted. For example, catastrophic interpreta-
tions are characterized by exaggerated negative rumination, amplification of the symp-
toms, and helplessness [13, 14]; they have furthermore been shown to be associated 
with negative emotions. In particular, catastrophizing is associated with specific, symp-
tom-related, fear which in turn incites avoidance behaviour and in the long term con-
tributes to disability [9, 10, 15, 16]. Also in MS there is evidence that patients who 
catastrophize about their fatigue and who attribute their fatigue to their illness are 
more likely to focus their attention on signs of fatigue and to interpret the conse-
quences of fatigue as a sign of physical damage [6].  
 The aim of the current study was to compare the assumptions of a biomedical 
model with a cognitive behavioural conceptualization of fatigue and physical disability 
in MS patients. The hypothesis based on the cognitive behavioural model was that 
patients who catastrophically interpret their fatigue also report more fatigue-related 
fear and avoidance behaviour, and hence are more physically disabled and depressed 
[6, 7]. In contrast, the biomedical model assigns a more prominent role to disease se-
verity in the case of fatigue as well as depression [17-19]. Hence, it considers catastro-
phizing about fatigue, and fatigue-related fear and avoidance behaviour, as conse-
quences rather than precursors of physical disability.  
 By applying structural equation modelling (SEM), we tested whether structural 
relationships between substantively meaningful variables showed a better fit with ei-
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ther of the theoretical models. In line with evidence in other populations [8-11, 13], we 
expected to find that the overall test of the cognitive behavioural model would show a 
better fit than that of the traditional biomedical model. A comparison of cognitive be-
havioural and biomedical models of fatigue is not merely of theoretical importance; it 
also has potential clinical implications, as effective treatments for fatigue in patients 
with MS are scarce.  
Methods 
Participants 
Participants were recruited from the hospital databases of the Departments of Neurol-
ogy of the Maastricht University Medical Centre and Atrium Medical Centre Parkstad 
Heerlen. A total of 404 patients aged 18 years and older and diagnosed with clinically 
definite MS [20], were eligible for inclusion. To preserve patient confidentiality, the 
initial letters were sent to these 404 MS patients by their treating neurologist. In total 
294 patients were willing to participate and contacted the researchers (73% response 
rate) and all these 294 patients were screened by telephone to verify eligibility. Four 
patients were excluded because they had problems understanding the questionnaires. 
Furthermore, ten patients who had suffered from a (recent) exacerbation and were 
taking corticosteroids were included 4 weeks later when their condition was stabilized. 
A total of 290 patients were sent a patient information letter, a consent form and ques-
tionnaires. Only 20 patients failed to return these forms, leaving the total sample at 270 
(93% response rate). The medical ethics committee of both the Maastricht University 
Medical Centre and Atrium Medical Centre Parkstad Heerlen approved the project and 
each patient gave their informed consent. 
Measures 
The use of psychopharmaca and demographic information, including sex, age, level of 
education, marital status, and employment status was obtained by a demographic 
inventory filled out by the MS patients. The level of education was assessed by classify-
ing formal schooling in three groups: those with at most primary education (low level of 
education); those with junior vocational training (average level of education); and those 
with senior vocational or academic training (high level of education). Medical data, 
including disease severity, disease course, disease duration, and disease modifying 
drugs were collected from the hospital databases.  
 The Expanded Disability Status Scale (EDSS) [21], assessed by an experienced neu-
rologist familiar with EDSS recording (RH), provided a measure of disease severity. The 
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EDSS is divided into 8 functioning systems (pyramidal, cerebellar, brainstem, mental, 
bowel and bladder, visual-optic, sensory, and other). Impairment in each system is 
graded separately by means of neurological examination. EDSS scores range from 0 to 
10, with 0 being normal neurological examination and 10 being death due to MS. If 
there was no recent (>3 months) EDSS score available, the treating neurologist was 
consulted for a new assessment.  
 
All participants completed a battery of questionnaires assessing the following variables.  
 
The Abbreviated Fatigue Questionnaire (AFQ) [22] was used to measure physical fa-
tigue. The AFQ is a reliable and easily used instrument, consisting of four items ('I feel 
tired', 'I tire easily', 'I feel fit' and 'I feel physically exhausted'), which are rated on a 7-
point Likert scale with scoring alternatives ranging from “yes, that is true” to “no, that is 
not true”. After inverting the items 1, 2 and 4, a total score was calculated (range 4-28), 
with higher scores indicating a higher severity of physical fatigue.  
 Catastrophizing about fatigue was measured with the Fatigue Catastrophizing Scale 
(FCS), which is an adjusted version of the Dutch version of the Pain Catastrophizing 
Scale (PCS) [14, 23]. The PCS is a 13-item questionnaire that measures the frequency of 
catastrophizing thoughts displayed by patients about the pain they experience. Psy-
chometric properties of the PCS appeared adequate [24, 25]. We adapted the PCS by 
replacing the word ‘pain’ by the word ‘fatigue’ in all items. Scoring alternatives ranged 
from ‘strongly disagree’ to ‘strongly agree’. Three MS-related items were added (“When 
I am tired, this is a signal there is something wrong in my brain”, “When I am tired, this 
is a warning for physical decline”, “When I am tired, this is a sign that my MS is getting 
worse”). The FCS consists of 16 items, with scores ranging from 0-64 and with higher 
scores indicating higher intensity. 
 The fatigue version of the Tampa Scale for Kinesiophobia (TSK-F) [10] was used to 
measure fatigue-related fear and avoidance behaviour. The TSK-F is an adapted version 
of the original 17-item TSK for chronic pain [26, 27], and measures the extent to which 
patients believe that fatigue associated with physical activity is a sign of body damage, 
and the extent to which they avoid physical activity because of these beliefs. To make 
this questionnaire adequate for fatigue the word ‘pain’ was replaced by the word ‘fa-
tigue’ and the former item was adjusted, e.g. “I am afraid that I might make my symp-
toms worse if I exercise”, instead of “ I'm afraid that I might injure myself if I exercise”. 
Each item is provided with a 4-point Likert scale with scoring alternatives ranging from 
‘not at all’ to ‘all the time’ (with scores ranging from 17-68).  
 Depression was measured with the subscale depression of the Hospital Anxiety and 
Depression Scale (HADS) [28]. The HADS is specially designed to screen physically ill 
patients for anxiety and depression and does not include somatic symptoms. The de-
pression scale consists of 7 items, with depression scores ranging from 0-21 and with 
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higher scores indicating higher intensity. Scores over 7 indicate that patients are likely 
to be depressed. Reliability and validity are adequate for several clinical populations 
[29, 30].  
 The physical dimension of the Dutch version of the Short Form Health Survey (SF-
36) [31] was used to measure physical disability. The physical dimension includes four 
subscales, viz.: physical functioning, role limitations due to physical health problems, 
bodily pain and general health. The standardized scores (ranging from 0 to 100) of each 
subscale were added to lower scores indicating more physical disability. The SF-36 was 
found to have adequate psychometric properties [31].  
Analysis 
Data analysis was performed using the SPSS 15.0 version for Windows. Data were 
checked for missing values, normality and outliers. Of the 270 returned questionnaires, 
8 cases were excluded because too many values were missing (≥25% of items of ques-
tionnaire missing or ≥50% if a questionnaire consisted of 4 items). For all other cases 
(N=26) all missing values were random and imputed by inserting the mean of the re-
maining non-missing items of the subscale. Any variables that were significantly skewed 
(skewness <-1 or >1) were transformed appropriately before parametric testing. De-
scriptive statistics were used to describe the sample. Cronbach’s alpha was used to test 
reliability of all questionnaires. Pearson correlations were used to analyze relations 
between all variables. The models were tested and modified with the help of the com-
puter program AMOS 16.0.1. [32]. We tested a measurement model with directly ob-
served variables in which the error terms associated with the observed variables were 
left free to be estimated and also were assumed to be uncorrelated with each other. In 
line with the recommendations of Byrne [33], model fit was assessed using several fit 
indices, respectively chi-square statistic (Chi2), goodness-of-fit index (GFI), adjusted 
goodness-of-fit index (AGFI), root mean square error of approximation (RMSEA), com-
parative fit index (CFI) and the consistent akaike information criteria (CAIC). According 
to guidelines for SEM, the data were considered to fit the model if the Chi2, a statistical 
test of lack of fit resulting from overidentifying restrictions placed in a model, was not 
significant. Chi2 is the most frequently used goodness-of-fit index. A statistically signifi-
cant Chi2 indicates that a significant amount of observed covariance between items 
remains unexplained by the model, while a non-significant Chi2 implies a good fit of the 
model to the data. However, this index is sensitive to sample size, which is a disadvan-
tage [34]. In a small sample, a poor fit may result in a non-significant Chi2, indicating a 
good fit. In a large sample, a good fit may result in a significant Chi2 indicating a poor fit. 
Values of the GFI and the AGFI assessing the extent to which a model provides a better 
fit compared to no model at all, should be high, respectively above 0.95 and 0.85. The 
RMSEA was taken into account as a measure of discrepancy per degree of freedom. 
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RMSEA estimates lack of fit in a model compared to a perfect model, and should there-
fore be small. RMSEA values up to 0.05 indicate a close fit, whereas values ranging 
between 0.08 and 0.10 indicate a mediocre fit and those greater than 0.10 indicate a 
poor fit. The CFI represents the proportionate improvement in model fit by comparing 
the target model with a baseline model, usually a null model in which all the observed 
variables are uncorrelated; CFI values larger than 0.95 indicate an adequate fit. The 
CAIC is used in the comparison of two or more not-nested models, with smaller values 
representing a better fit.  
Results 
Patient sample 
A total of 262 outpatients (69 male, 193 female) were included. Their mean age was 
47.6 years (SD=11.7, range 21-80). Most of them (n=136) had a relapsing remitting 
disease course, while 67 patients had a secondary progressive, and 59 patients a pri-
mary progressive course. The average EDSS score was 4.0 (SD=2.2, range 0-8), reflecting 
a moderate disease severity. See table 1 for a summary of all patient characteristics.  
 
Table 1. Patient characteristics (n=262) 
Sex (% male / % female)  26 / 74  
Age in years (mean, (SD))  47.6 (11.7)  range 21.1-79.9 
Disease duration in years (mean, (SD))  8.6 (7.9) range 0.1- 53.7 
Disease course (% RR / % SP / % PP)  52 / 26 / 22  
EDSS (mean, (SD))  4.0 (2.2)  range 0-8 
HADS-depression (% <8 / % ≥8)  68 / 32  
Use of disease modifying drugs (% yes / % no)  43.5 / 56.5  
Use of psychopharmaca (% yes / % no) 
Level of education (% low / % average/ % high)  
26 / 74 
28 / 36 /36 
 
Marital status (% partner / % no partner) 78 / 22  
Employment status (% working / % not working) 30 / 70  
RR= relapsing remitting; SP= secondary progressive; PP= primary progressive; EDSS= Expanded Disability Status 
Scale; HADS= Hospital Anxiety and Depression Scale. 
 
Table 2 presents means, standard deviations, ranges, Cronbach’s alphas for all variables 
under study, as well as their intercorrelations (Pearson). All questionnaires had excel-
lent internal consistency as measured by Cronbach’s alpha, ranging from 0.82 to 0.91. 
Although all intercorrelations were statistically significant (p<0.01), the strongest asso-
ciation was found between catastrophizing about fatigue and fatigue-related fear and 
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avoidance behaviour. Higher levels of catastrophizing about fatigue were related to 
higher levels of fatigue-related fear and avoidance behaviour (r=0.64, p<0.001). The 
lowest association was found between disease severity and catastrophizing about fa-
tigue (r=0.17, p<0.01).  
 
Table 2. Means, standard deviations (SD), ranges, Cronbach’s alphas (α) and Pearson-correlations of all measures  
 Mean (SD) Range α 2 3 4 5 6 
1. Disease severity (EDSS) 4.0 (2.2)  0-8 - -.27**  .17*  .25**  .26** -.58** 
2. Physical fatigue (AFQ) 19.8 (6.6) 4-28 .91 - .56** .37** .49** -.60** 
3. Catastrophizing about fatigue (FCS) 20.4 (15.1) 0-64 .91 - - .64** .57** -.57** 
4. Fatigue-related fear and avoidance (TSK-F) 37.9 (9.4) 17-61 .82 - - - .50** -.56** 
5. Depression (HADS-D) 6.0 (4.2) 0-21 .83 - - - - -.57** 
6. Physical disability (SF-36) 246.3 (87.0) 15-390.91 - - - - - 
EDSS= Expanded Disability Status Scale; AFQ= Abbreviated Fatigue Questionnaire; FCS= Fatigue Catastrophizing 
Scale; TSK-F= Fatigue version of the Tampa Scale for Kinesiophobia; HADS= Hospital Anxiety and Depression 
Scale; SF-36= Short Form Health Survey. *p<0.01; ** p<0.001. 
Structural equation modelling analyses 
An overview of all goodness-of-fit indices is displayed in Table 3. Figure 1 depicts the 
SEM results for the cognitive behavioural model (model 1). None of the goodness-of-fit 
indices satisfied the a priori criteria for a good model fit. Although all hypothesized 
relationships of the biomedical model (model 2, figure 2) were statistically significant, 
SEM analyses of this model also revealed an unacceptable fit. As such, neither of the 
initial models that were designed a priori fit our data.  
 Although SEM is generally used to test pre-specified conceptual models, it is often 
also applied in an exploratory way [32]. Since there is empirical support for both cogni-
tive behavioural and biomedical factors in explaining MS-related fatigue, it was antici-
pated that the exploratory use of SEM, including factors of both models, would improve 
the overall understanding of fatigue and physical disability in MS. To explore whether a 
better fitting model existed, we adapted the cognitive behavioural model by adding 
relationships suggested by the modification indices (MI) provided by the AMOS pro-
gram [33, 34]. A MI represents the value that Chi2 is expected to decrease if such a 
relationship would be included. In this way new causal relationships can be identified 
that improve the model. Because SEM is a theoretically driven technique we only added 
theoretically meaningful modifications. We subsequently added the relationships be-
tween disease severity and physical disability (MI=80.10); physical disability and depres-
sion (MI=33.77); depression and catastrophizing about fatigue (MI=12.97); and disease 
severity and fatigue-related fear and avoidance behaviour (MI=10.56). Finally, we suc-
cessively deleted non-significant relationships in order to explain as much variance as 
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possible with a minimum of variables (principle of maximum parsimony). We deleted 
two non-significant relationships, respectively the path from disease severity to fatigue 
and from fatigue-related fear and avoidance behaviour to depression and subsequently 
refitted each model. The final model (see Table 3 and Figure 3) had acceptable GFI, 
AGFI, RMSEA and CFI values, and also produced the lowest CAIC value, indicating the 
best fit of all the models proposed.  
 
Table 3. Goodness-of-fit summary for the models tested (n=262) 
 Chi2 (df) RMSEA GFI AGFI CFI CAIC 
Model 1. Cognitive behavioural model 202.77 (8)** 0.305 0.814 0.512 0.709 288.16 
Model 2. Biomedical model 107.76 (7)** 0.235 0.902 0.706 0.850 199.71 
Model 1a: added: 
 Disease severity to physical disability 
 
102.15 (7)** 
 
0.228 
 
0.886 
 
0.659 
 
0.858 
 
194.11 
Model 1b: added: 
 Physical disability to depression 
 
52.54 (6)** 
 
0.172 
 
0.940 
 
0.789 
 
0.931 
 
151.06 
Model 1c: added: 
 Depression to catastrophizing 
 
25.93 (5)** 
 
0.127 
 
0.969 
 
0.870 
 
0.969 
 
131.02 
Model 1d: added: 
 Disease severity to fear-avoidance 
 
14.86 (4)* 
 
0.102 
 
0.982 
 
0.905 
 
0.984 
 
126.52 
Final model (model 3): deleted: 
 Non significant paths 
 
17.44 (6)* 
 
0.085 
 
0.979 
 
0.925 
 
0.983 
 
115.96 
GFI= goodness-of-fit index; AGFI= adjusted goodness-of-fit index; RMSEA= root mean square error of approxi-
mation; CFI= comparative fit index; CAIC= consistent akaike information criteria.  
Catastrophizing= catastrophizing about fatigue; Fear-Avoidance= Fatigue-related fear and avoidance behaviour 
* p<0.01; ** p<0.001. 
 
Disease 
severity
Physical
Disability Depression
Fatigue
Catastrophizing
Fear-
Avoidance
-.03
.17*
.43**.55**
-.47**
.43**
-.45**
(.24)
(.40)
(.29)
(.30)
(.37)
Disease 
severity
Physical
Disability Depression
Fatigue
Catastrophizing
Fear-
Avoidance
.64**
.56**
-.41**
.26**
.45**-.34**
0.16*
-.30**
(.07)
(.31)
(.26)
(.61)
(.41)
 
Figure 1. Cognitive behavioural model Figure 2. Biomedical model 
Fear-Avoidance= Fatigue-related fear and avoidance behaviour; Catastrophizing= catastrophizing about fatigue. 
Values shown are standardized regression coefficients. Explained variances are provided in parentheses.  
*p<0.01; **p<0.001. 
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Disease 
severity
Physical
Disability Depression
Fatigue
Catastrophizing
Fear-
Avoidance
-.50**.16*
-.33**
.54**
-.52**
-.44**
.22**
.36**.33**
(.33)
(.39)
(.51)
(.43)
(.43)
 
Figure 3. Final model 
Fear-Avoidance = Fatigue-related fear and avoidance behaviour; 
Catastrophizing = catastrophizing about fatigue. Values shown are 
standardized regression coefficients. Explained variances are
provided in parentheses. *p<0.01; **p<.0.001 
Discussion 
The aim of the current study was to compare the assumptions of a traditional biomedi-
cal model with those of a cognitive behavioural model. In particular, we tested and 
explored the role of catastrophic (mis)interpretations on MS-related fatigue and physi-
cal disability. In contrast to the biomedical model, the cognitive behavioural model’s 
main assumption is that fatigue is not perpetuated or worsened by disease severity or 
associated symptoms, but by the interpretation of these symptoms by the patient.  
SEM revealed that neither of the initial models showed adequate fit of our data. By 
using the modification indices, the cognitive behavioural model was modified by adding 
several theoretically meaningful relationships and deleting non-significant relationships. 
The final model met all the preset fit criteria, and was generally in line with the fear-
avoidance model of chronic pain [13]. Catastrophic interpretations of fatigue such as 
“When I am tired, this is a signal there is something wrong in my brain” and “When I am 
tired, this is a sign that my MS is getting worse”, seemed to be a key factor and medi-
ated the relationship between fatigue and fatigue-related fear and avoidance behav-
iour. Hence, catastrophizing is an important target for cognitive behavioural interven-
tions during which dysfunctional fatigue-related thoughts can be challenged [35]. In this 
kind of a cognitive treatment, patients are given the opportunity to test the credibility 
of their beliefs in catastrophic outcomes, and to correct these accordingly. 
 Furthermore, depression appeared to play an important role in our model. Depres-
sion was a negative consequence of increased disability, and directly contributed to 
fatigue and catastrophizing about fatigue. Depression is known to be the most common 
psychiatric disorder in MS, with an estimated prevalence ranging between 27% and 54% 
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[36-39]. Therefore, we recommend the screening of fatigued MS patients for depres-
sion and the treatment of this psychiatric co-morbidity. 
 In contrast to the fear-avoidance model in chronic pain, disease severity played a 
prominent role in the adjusted cognitive behavioural model of fatigue in MS. Disease 
severity indirectly contributed to fatigue, through fatigue-related fear, avoidance be-
haviour, and physical disability. MS patients with higher levels of disease severity seem 
to experience more fear-related cognitions, and hence more physical disability. It is 
possible that information about the disease heightens the fear of fatigue, which may 
lead to a decrease in physical activity, that in turn may cause an increase in fatigue 
levels.  
 Our results are in line with the findings of the first randomized clinical trial of cogni-
tive behavioural therapy (CBT) for fatigue in MS patients [40]. In this study, eight weekly 
sessions of CBT appeared to be more effective in reducing self-reported fatigue than 
relaxation therapy. Not only fatigue, but also fatigue-related disability and depression 
showed a significant decrease. The intervention in this study was a general one that 
included only one session focused on changing negative thoughts. The effectivity of 
interventions might be increased by challenging cognitive misinterpretations of MS-
related fatigue more systematically.  
Limitations 
There are several limitations to this study, which should be taken into account when 
interpreting the results and which may be addressed in future studies. First of all, the 
design is cross-sectional, making it impossible to draw firm conclusions about causal 
relationships between variables. Prospective and longitudinal studies are needed to 
infer causality. Secondly, because of our relatively small sample size, we were not able 
to split our sample in order to cross-validate our final model. Thirdly, we used a postal 
questionnaire to collect our data. Although we had a favourable response rate for a 
postal questionnaire, we were not able to examine the differences between responders 
and non-responders. As a result, a potential selection bias interfering with the present 
results cannot be excluded. Fourthly, our measures for catastrophizing about fatigue 
(FCS), and fatigue-related fear and avoidance behaviour (TSK-F) are quite new. Although 
both questionnaires are adaptations of valid instruments and show excellent internal 
consistency, their reliability and validity need to be established further. Finally, all data, 
including those on physical disability, were self-reported and therefore amenable to 
retrospective bias and social desirability effects. Furthermore, it is possible that strong 
associations between self-reported variables are the result of shared-method variance 
[41]. Future studies should also include more objective measures such as an acceler-
ometer, which is a reliable and valid measure of daily activity levels [42, 43].  
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Conclusions  
Despite the limitations described above, this study shows that there are a number of 
relevant factors besides the severity of disease symptoms to be considered when trying 
to explain fatigue and physical disability in MS patients, viz.: catastrophizing about 
fatigue, and fatigue-related fear and avoidance behaviour, in combination with depres-
sion, are also relevant factors. Assuming that the final model is stable, the present re-
sults may not only contribute to a better understanding of fatigue and physical disability 
in MS patients, but also suggest (additional) psychological interventions that will help 
MS patients to achieve their daily life goals. 
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Introduction 
Fatigue is a frequent and disabling symptom in patients with multiple sclerosis (MS), 
and although it has been studied for over 25 years, its pathogenesis is still poorly un-
derstood. The evidence for explanatory biological factors is at best conflicting and a 
psychological approach may be helpful to further explain and treat fatigue in MS. 
Therefore the general aim of this thesis was to better understand the concept of MS-
related fatigue from a psychological perspective. As such the focus was on identifying 
relevant psychological factors in explaining MS-related fatigue and their added value to 
biological factors such as disease severity and cerebral white matter lesions.  
 
The specific questions were: 
- What is MS-related fatigue and is it related to psychological factors? 
- Is cognitive functioning negatively affected by fatigue? 
- How disease specific is fatigue in MS? Is fatigue associated with disease-related 
factors and is the contribution of disease severity and psychological factors in MS 
different from that in patients with a non-neurological chronic auto-immune dis-
ease? 
- Are negative affectivity and depression risk factors for fatigue in MS? 
- Does worrying about fatigue increase MS-related fatigue and physical disability? 
 
In order to answer the first question we reviewed the literature to define MS-related 
fatigue and to select relevant psychological factors (Chapter 2). Next, we examined two 
data samples in order to answer the remaining questions, which address the relation-
ship between fatigue and the respective psychological factors, and more specifically, 
the relationship of fatigue to cognition (Chapter 3), its disease specificity, and the ex-
tent to which it can be explained by depression, negative affectivity (Chapter 4 and 5), 
and cognitive behavioural factors (Chapter 6). In this concluding chapter the main find-
ings are summarized and related topics are discussed. Furthermore, we consider some 
methodological issues, make recommendations for future research and discuss clinical 
implications.  
Main findings 
• MS-related fatigue is defined as a subjective experience that has both physical and 
mental aspects (Chapter 2).  
• When studying the relationship between mental fatigue and cognition in MS, con-
struct validity is an area of concern (Chapter 2 and 3).  
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• Mental fatigue, together with anxiety and depression, accounts for a substantial 
part of the total variance of cognitive complaints (Chapter 3). 
• Subjective fatigue does not contribute to cognitive performance (Chapter 3). 
• MS patients experience higher levels of fatigue than healthy participants and than 
patients with ulcerative colitis (UC), a non-neurological auto-immune disease 
(Chapter 4 and 5).  
• Levels of objective mental fatigue, defined as a decrease in performance during a 
vigilance task, do not differ between MS patients, UC patients and healthy partici-
pants (Chapter 4).  
• Cerebral white matter lesion load is not related to mental fatigue (Chapter 4). 
• Disease severity is an independent contributor to physical fatigue, but not to men-
tal fatigue in both MS and UC patients (Chapter 4 and 5).  
• Depression is related to both physical and mental fatigue, whereas negative affec-
tivity is only related to mental fatigue, in both MS and UC patients (Chapter 5). 
• The contribution of disease severity, depression, and negative affectivity to fatigue 
is equal in both MS and UC patients and is not MS-specific (Chapter 5).  
• Disease severity contributes indirectly to physical fatigue, through fatigue-related 
fear and avoidance behaviour, and physical disability (Chapter 6).  
• Depression appears to be a negative consequence of physical disability and it con-
tributes directly to both fatigue and catastrophizing about fatigue (Chapter 6). 
• Not just the severity of MS symptoms, but catastrophizing about fatigue and fa-
tigue-related fear and avoidance behaviour, in combination with depression, are 
significant determinants of fatigue and physical disability levels in MS patients 
(Chapter 6). 
The concept of fatigue in MS: definition and assessment 
As described in Chapter 2, the consensus definition of MS-related fatigue [1] implies 
that fatigue has both physical and mental aspects and therefore should be assessed 
multidimensionally. The findings described in this thesis demonstrate the importance of 
such a multidimensional assessment and support the idea that physical and mental 
fatigue have different correlates. For instance, as described in Chapter 5, both in the 
case of MS and UC patients disease severity was an independent contributor to physical 
fatigue, but not to mental fatigue. In contrast, in both these patients groups negative 
affectivity was related to mental fatigue only. This multidimensional nature has also 
been recognized in other studies in the case of MS [2-5] as well as other chronic dis-
eases [6, 7], which supports the differentiation between physical and mental fatigue. 
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MS-related fatigue is not only defined as a multidimensional symptom, but also as a 
subjective experience; therefore the patient’s report is actually the only information 
available with which to rate fatigue severity [8]. Nevertheless, several attempts have 
been made to assess fatigue objectively in order to overcome the limitations of self-
report questionnaires, such as retrospective bias. A recurrent approach is to operation-
alize mental fatigue in terms of a decrease in performance during a task that requires 
sustained mental effort [9]. In the study described in Chapter 4, we used such an ap-
proach. Our results showed that MS patients experienced more mental fatigue than 
healthy participants and UC patients, but that there were no differences in mental 
fatigue between all groups when fatigue was objectively measured by using a perform-
ance task. Although the latter finding is in contrast to other findings in MS patients [10, 
11], numerous investigations of various clinical populations exist which show that there 
is no change in mental task performance relative to controls [12].  
 As already suggested by DeLuca [13], the experience of fatigue does not imply 
diminished performance. Although self-reported fatigue and diminished task perform-
ance are both methods with which to assess fatigue, a strong relationship between 
these two assessments is not obvious. Indeed, there is no significant relationship be-
tween both assessments and this conclusion is also supported by evidence in various 
clinical populations [9]. This is similar to the lack of an association between cognitive 
complaints and cognitive performance, based on neuropsychological assessment [14-
20].  
 While there is little overlap between the subjective and objective assessment of 
fatigue, the objective method of fatigue assessment does share a component with that 
of cognition in terms of performance, which leads to a problem of construct validity. 
Given the method used to objectify mental fatigue, a decrease in performance is equal 
to a decrease in cognitive performance, which may reduce the usefulness of objective 
measures of fatigue in research and clinical practice that is related to both fatigue and 
cognition. Hence, even if we do find sensitive measures with which to assess mental 
fatigue objectively in MS patients, the experience of fatigue and related complaints 
must be the starting point in daily practice [21]. As such, a subjective assessment would 
be sufficient for assessing both mental and physical fatigue.  
The impact of fatigue on cognitive functioning in MS  
While the previous paragraph ended with a plea for subjective assessment only, which 
was based on the relevance of the experience and the problem of construct validity of 
the so-called objective assessment method, our findings in Chapter 3 indicate the same 
problem of construct validity for the subjective assessment method. Besides fatigue, 
cognitive complaints are very common in patients with MS [22-24]; yet both subjective 
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mental fatigue and cognitive complaints are generally measured by using question-
naires with comparable items (e.g. concentration problems), and therefore measuring 
mainly the same construct. This problem of construct validity has also been established 
by the high correlation found between subjective mental fatigue and cognitive com-
plaints (Chapter 3).  
 In Chapter 3, we investigated the contribution of physical and mental fatigue to 
both cognitive complaints and cognitive performance respectively. Our study revealed 
that mental fatigue, together with anxiety and depression, accounted for a substantial 
part of the total variance of cognitive complaints. This result is in accordance with other 
findings both in MS and in other populations, which showed that cognitive complaints 
are often determined by such non-cognitive factors [14-16, 25-30].  
 Since cognitive complaints do not necessarily predict deficits in cognitive perform-
ance [14-16], it is not surprising that we failed to find a relationship between fatigue as 
a subjective experience and cognitive performance measures (Chapter 3). While one 
would expect, as we also did, fatigue to be related to cognitive performance in neuro-
psychological tests that require attention and executive functioning, neither physical 
nor mental fatigue appeared to be related to mental speed, attention, memory or ex-
ecutive functioning. Our findings are in line with recent work by Morrow et al. [31], who 
concluded, based on both cross-sectional and longitudinal findings, that there is little 
empirical support for a relationship between subjective fatigue and cognitive perform-
ance.  
 These results might question the clinical assumption that neuropsychological per-
formance is adversely affected by fatigue [32]. The present findings argue against the 
suggestion that test sessions should be shortened. In order to ensure the valid assess-
ment of cognitive performance in fatigued patients one does not need to reduce the 
number of tests. On the contrary, given the impact of cognitive impairment on daily life, 
and its heterogeneity in MS, both routine and extensive neuropsychological assessment 
is recommended to detect cognitive impairment [22, 33, 34]. In addition, and also sup-
ported by the present findings, we conclude that one cannot rely on MS patients’ self-
reports to obtain a reliable estimate of cognitive functioning. 
The specificity of fatigue in MS 
The focus of the studies described in Chapter 4 and 5 was on the disease specificity of 
fatigue in MS. Because fatigue is a common symptom in chronic diseases that might be 
caused by many non-specific disease-related factors [35], we compared levels of fatigue 
in MS not only to those in healthy control participants (Chapter 4), but also to levels of 
fatigue in patients with a comparable non-neurological auto-immune disease (Chapter 4 
and 5). Ulcerative colitis (UC), an inflammatory bowel disease, was taken as an example 
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of a chronic auto-immune disease without obvious CNS involvement. UC resembles MS: 
it is chronic, intermittent, and disabling; and it is characterized by a lifetime risk of re-
lapses that start between the ages of 20 and 40 [36]. As shown in the study described in 
Chapter 4, MS patients experienced significantly higher levels of mental fatigue than 
both healthy control participants and UC patients. Furthermore, the study described in 
Chapter 5 revealed that the levels of both physical and mental fatigue were significantly 
higher in MS patients than those in UC patients. Our results are in line with the findings 
of other studies that compared fatigue in MS to that in healthy controls and to several 
other somatic populations [2, 4, 8, 37-39]. This suggests that fatigue is specifically re-
lated to MS, and not just an non-specific consequence of disease and handicap. How-
ever, as described in Chapter 5, its correlates are not MS specific. That is, there are no 
differences in the contribution of disease severity, depression and negative affectivity 
to both physical and mental fatigue in the different patients groups.  
 So far, there is no evidence that pathophysiological mechanisms play a major role 
in contributing to fatigue in MS, which also questions the MS specificity of fatigue. For 
instance, the total amount of cerebral white matter lesions is not related to mental 
fatigue (Chapter 4). Although the existence of white matter lesions is part of the clinical 
diagnosis of MS [40], using structural imaging is of course an underestimation of the 
complexity of the CNS mechanisms in MS. Recent views propose that MS no longer 
primarily be considered a white matter disease, but rather a neurodegenerative dis-
ease, in which acute inflammatory demyelination and both axonal and grey matter 
damage are involved [41]. Several recent imaging studies show that fatigue in MS is 
related to both subcortical and cortical grey matter atrophy, especially in the frontal 
areas [42-44]. Using positron emission tomography, Roelcke et al. [45] demonstrated 
that fatigue is associated with reduced cerebral glucose metabolism in frontal areas and 
basal ganglia. These findings suggest that fatigue is associated with a disruption of brain 
networks involved in cognitive functioning, especially attentional and executive proc-
essing.  
 Recently, there has been increased interest in the use of functional MRI (fMRI), 
which measures the hemodynamic response related to neural activity in the CNS and 
offers a sensitive measure of changes in brain functioning [46]. Using fMRI, MS patients 
showed an increased activation in the basal ganglia and frontal regions during cognitive 
performance measured by a modified Symbol Digit Modalities Task (mSDMT) [13], 
which was interpreted as a correlate of mental fatigue in terms of a compensatory 
mechanism to complete the mSDMT. Like patients with traumatic brain injury, there is 
evidence that MS patients require much more cerebral activation to compensate for 
processing deficits while undertaking effortful and sustained cognitive tasks than 
healthy controls [47, 48]. The additional cerebral activation that is required to perform 
what was previously a more automatic cerebral routine, is hypothetically a plausible 
mechanism underlying central fatigue [13].  
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Central fatigue  
In Chapter 2, we mentioned the distinction between central and peripheral fatigue, as 
suggested by Chaurdhuri and Behan [6]. Central fatigue, in contrast to neuromuscular 
or peripheral fatigue, is defined as the failure to initiate and/or sustain attentional tasks 
(mental fatigue) and physical activities (physical fatigue) that require self-motivation. 
Although it has been suggested that central fatigue is the major cause of fatigue in 
chronic disease, including MS [49], it is questionable whether central fatigue explains 
the experience of fatigue in clinical populations. From a theoretical point of view, the 
distinction between central and peripheral fatigue seems a clear one, but in general 
practice this distinction is difficult. For instance, physical fatigue can be the result of 
muscle fatigue (peripheral processes) or of brain control over the muscle (central proc-
esses) [12]. Fatigue is influenced by a complex interaction between peripheral and 
central factors and the degree to which peripheral and/or central processes are in-
volved is often difficult to determine, as their contribution may vary between activities 
and even within the same activity.  
 The findings of several studies described above [13] correspond to the hypothesis 
of Chaudhuri and Behan [49] that damage to the basal ganglia and their circuitry pre-
disposes one to symptoms of central fatigue. However, there is no direct evidence that 
this mechanism is relevant. Although fMRI studies seem promising, this technique is 
less specific and therefore its use is questionable [46].  
 In sum, even though the literature regarding pathophysiological mechanisms in the 
explanation of MS-related fatigue is increasing, the suggested mechanisms are mainly 
hypothetical; even if evidence does exist, it has to be kept in mind that disease-related 
variables can only explain a small part of the variance. In conclusion, despite some 
circumstantial evidence, there is no definite proof for a disease-specific origin of fatigue 
in MS. Therefore our findings support a trans-diagnostic approach to fatigue. 
Fatigue in MS explained by negative affectivity and depression 
In Chapter 5 we studied the relationship between fatigue and respectively negative 
affectivity and depression. This study revealed that whereas negative affectivity con-
tributed only to mental fatigue, depression contributed to both physical and mental 
fatigue. In our integrated model, which is described in Chapter 6, depression was also 
directly related to physical fatigue.  
 However, because our studies were cross-sectional, we cannot definitely answer 
the question whether depression and negative affectivity are risk factors for fatigue in 
MS. To the best of our knowledge, no longitudinal studies that focus on the relationship 
between negative affectivity and fatigue in MS have been conducted. However, there is 
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major evidence that negative affectivity predicts several physical conditions, as has 
been shown in a large longitudinal cohort twin study [50]. With regard to depression, 
our findings are in line with two available intervention studies that suggest that fatigue 
is caused by depression [51, 52]. Also recent longitudinal findings (n=2768) support this 
relationship between fatigue and depression in MS [53]. Baseline levels of fatigue, de-
pression, and pain accounted for about 35% of the variance in one-year follow-up fa-
tigue scores.  
 There is evidence that these three symptoms, i.e. fatigue, depression, and pain 
form a symptom cluster in MS patients [54] and other chronic populations, including 
patients with rheumatoid arthritis [55] and cancer survivors [56]. A symptom cluster is 
defined as a stable group of two or more concurrent symptoms that are related to one 
another and independent of other symptoms or symptom clusters [57]. It has been 
suggested that symptoms in a cluster could share covariance, have a common aetiol-
ogy, or have a common influence on patient outcomes. The existence of a symptom 
cluster in MS may provide evidence for shared common mechanisms, such as decreased 
activity of dopaminergic, serotonergic and noradrenergic systems [58], or increased 
levels of pro-inflammatory cytokines [59, 60]. Also psychological variables, such as 
negative affectivity, can contribute to such a symptom cluster [50]. Furthermore, these 
symptoms might predict physical activity, while MS patients who are physically active 
report lower levels of depression, fatigue, and pain than those who are less physically 
active [54].  
Why fatigue in MS can become chronic: a model of perpetuation  
In Chapter 6, we investigated the role of catastrophic (mis)interpretations of fatigue on 
both fatigue and physical disability in MS patients. We compared a cognitive behav-
ioural model with a traditional biomedical model with the help of structural equation 
modelling (SEM). We found evidence in favour of an integrated cognitive behavioural 
model, in which catastrophizing about fatigue was a key factor that mediated the rela-
tionship between fatigue and fatigue-related fear and avoidance behaviour. In contrast 
to the fear-avoidance model in chronic pain [61], disease severity played a prominent 
role in the adjusted cognitive behavioural model of fatigue in MS. Disease severity indi-
rectly contributed to fatigue, through fatigue-related fear and avoidance behaviour as 
well as physical disability. Depression appeared to be a negative consequence of physi-
cal disability, and contributed directly to both fatigue as well as to catastrophizing 
about fatigue. The findings of Chapter 6 show, in line with evidence in MS [62, 63] and 
cancer survivors [64, 65], that patients who catastrophize about fatigue are prone to 
maintain their fatigue symptoms. Because MS is an unpredictable and incurable dis-
abling disease, patients run the risk of negative thinking [66]. Furthermore, as our 
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model shows, those patients who are depressed are especially liable to catastrophize 
about fatigue. In sum, our study revealed that physical fatigue is not just a consequence 
of disease severity, but that catastrophizing about fatigue, and fatigue-related fear and 
avoidance behaviour, in combination with depression, were significant determinants of 
fatigue and physical disability levels in MS patients. 
 Our model is in line with the model of predisposing, precipitating and perpetuating 
factors that was developed to better understand fatigue and medically unexplained 
symptoms in general [67-69]. Predisposing factors are characteristics of a patient that 
increase the chance to develop fatigue as soon as a precipitating factor is present. Ex-
amples of such predisposing factors are a genetic predisposition, negative affectivity, 
physical inactivity, and female sex [67, 70]. The last may be an influencing factor in MS, 
because the majority of MS patients are female. However, most studies did not find a 
relationship between sex and fatigue in MS [71, 72]. Precipitating factors trigger the 
onset of fatigue in MS patients and include acute manifestations of illness or psycho-
logical stressors. It is known that fatigue often accompanies exacerbations and infec-
tions [73-75], but also life-events and stress [4]. Factors that may perpetuate fatigue 
once fatigue has been developed include specific cognitive and behavioural responses 
to fatigue and the physiological changes that may accompany these responses. These 
perpetuating factors, such as catastrophizing about the symptoms, symptom focusing, 
and the avoidance of physical activity, can maintain the fatigue symptoms over time. 
Also depression [52] and sleep disorders might be important perpetuating factors in 
MS-related fatigue [76].  
 The approach based on the idea of perpetuation can be useful in explaining why 
acute fatigue in MS patients can become chronic and it has been proven fruitful in the 
case of other populations [67-69]. Like the model of perpetuation, our model can be 
used trans-diagnostically and it differs from a more generic bio-psychosocial model by 
proposing a unique interaction of cognitive, behavioural, and physiological factors in 
the case of each individual. 
Methodological considerations 
In the next section we will mention the strengths and limitations of the studies de-
scribed in this thesis.  
Strengths 
Our study is unique in comparing MS patients with patients with UC, i.e. an auto-
immune disease without obvious CNS involvement. UC patients are especially appropri-
ate as controls, because they also suffer from a chronic, intermittent, and disabling 
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disease that most often starts between the ages of 20 and 40. Furthermore, fatigue and 
depression are common symptoms in both MS and UC, and like MS patients, UC pa-
tients are not characterized by chronic pain such as rheumatoid arthritis. 
 Overall, both the MS and UC patient samples are representative for clinical set-
tings. Our studies were conducted on MS patients at the Department of Neurology of 
the Maastricht University Medical Centre (Chapter 3, 4, 5 and 6), which combines a 
regional and academic function, and at the general district hospital in Heerlen (Atrium 
Medical Centre Parkstad) (Chapter 6). UC patients were found by using the Inflamma-
tory Bowel Disease (IBD) – South Limburg database of the Department of Gastroen-
terology of the MUMC, in which the UC patients are registered of all the three hospitals 
in South Limburg, i.e. the MUMC, the general district hospital in Heerlen (Atrium Medi-
cal Centre Parkstad), and the general district hospital in Sittard (Orbis Medical Centre).  
 Other strengths are: the adequate sample sizes (Chapter 3, 5 and 6); the multidi-
mensional assessment of fatigue; and the integration of biological and psychological 
factors. Finally, in contrast to several other studies, we were able to ensure that fatigue 
and depression were measured as separate entities, as the Hospital Anxiety and De-
pression Scale was selected to assess depression.  
Limitations 
Evaluation of our work from a methodological viewpoint brings limitations as well as 
strengths to light. For example, questions about the design of the studies, patient re-
cruitment, data collection and the assessment of the included variables.  
 The design we used in all studies was cross-sectional, which makes it impossible to 
draw firm conclusions about causal relationships between variables. Longitudinal stud-
ies with repeated measures and randomized clinical trials are needed to infer causality.  
 The comparability of the MS and UC samples (Chapter 4 and 5) is a point of discus-
sion. Overall, our patient samples are representative for clinical settings, but their re-
cruitment was different. Furthermore, we were not able to compare responders and 
non-responders and as a result there might be a selection bias interfering with the 
present results. 
 Most of the variables, such as fatigue, depression and physical disability, were self-
reported and therefore amenable to retrospective bias and social desirability effects. 
Furthermore, it is possible that strong associations between self-reported variables are 
the result of common-method variance [77]. To adjust for common-method variance 
one should obtain the measures of variables from different sources. For instance, future 
studies should include more than one self-report instrument in order to measure symp-
toms such as fatigue, and more objective tools for measuring daily activity levels, such 
as an accelerometer [78, 79].  
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Next, it is important to realize that we used a depression questionnaire to measure 
depressive symptoms and did not use a DSM-IV diagnosis of a depressive disorder [80]. 
To answer the question whether a depressive disorder contributes to fatigue in MS, 
future studies should use semi-structured clinical interviews conducted by a psycholo-
gist or psychiatrist. Furthermore, two questionnaires we used in the study described in 
Chapter 6, the Fatigue Catastrophizing Scale and the fatigue version of the Tampa Scale 
for Kinesiophobia are adaptations of valid instruments and show excellent internal 
consistency. However, their reliability and validity need to be established further.  
 Finally, the measurement of disease severity in both patient groups merits consid-
eration. Although both the Expanded Disability Status Scale and the Colitis Activity 
Index are widely used as outcome scales for monitoring the disease course of respec-
tively MS and UC patients, both scales are partly subjective. An overall biomarker of 
disease activity may enhance comparability across groups and would make it possible 
to study trans-diagnostic mechanisms such as cytokine-induced sickness behaviour. 
Unfortunately, no such valid and reliable biomarker is available as yet.  
Future research directions 
In future research, fatigue should be multidimensionally assessed, as we suggest be-
fore, and the assessment should include not only its severity but also the patient’s 
perception and appraisal of fatigue. Instruments such as the Fatigue Catastrophizing 
Scale (Chapter 6) or the Fatigue Quality List [81] might be applicable. Using such a quali-
tative approach might also enhance our understanding of the disease specificity of 
fatigue in chronic illness. Furthermore, other possible relevant variables, including pain, 
sleep disturbances, and medication use should be included.  
 Besides the need to deal with the above-mentioned limitations of our integrated 
cognitive behavioural model it should be replicated and its stability should be tested by 
cross-validation. Subsequently, single case design studies need to be conducted on 
highly fatigued MS patients who exhibit high levels of catastrophizing about fatigue and 
fatigue-related fear and avoidance behaviour. Catastrophic thoughts about fatigue 
should be detected and adjusted by the use of behavioural experiments. Finally, assum-
ing that our model appears to be stable and the results of the case studies are promis-
ing, the effectiveness of (cognitive) behavioural interventions should be tested in ran-
domized clinical trials. Given the evidence in chronic fatigue syndrome [68] and cancer 
survivors [82, 83], graded exercise therapy and cognitive behavioural therapy could also 
prove to be promising in MS. The positive findings of the first randomized clinical trial of 
cognitive behavioural therapy for fatigue in MS patients [84] already supported this 
conclusion. 
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Implications for clinical practice 
If our findings appear to be stable in future research, they may provide a useful frame-
work for identifying and treating MS patients at risk for chronic fatigue. With no current 
effective pharmacological therapy available [85, 86], the treatment possibilities for 
fatigued MS patients should focus on potentially modifiable variables with a high im-
pact on fatigue. Depression is the most common psychiatric disorder (27-54%) in MS 
and approximately 50% of the MS patients suffers from a depressive disorder during 
their disease course [87]. As such, and given its impact in the integrated model, depres-
sion is a relevant modifiable factor. It is important to mention that although depression 
is very common in MS, it is often undertreated [88, 89]. Furthermore, physical activity is 
an important modifiable factor to highlight, because MS is associated with reduced 
physical activity when compared with non-disease populations [90]. Furthermore, for 
many years, patients with MS have been advised to avoid exercise in order to minimize 
the risk of exacerbations and symptoms of fatigue [91-93]. Such advice is detrimental as 
it may contribute to the persistence of fatigue. The benefits of physical activity have 
been well documented in both healthy and somatic populations, and the potential for 
reducing mental and physical symptoms is substantial. Also there is evidence that exer-
cise therapy can be beneficial and improve the quality of life of MS patients [94, 95].  
 What should we advise Ms. A. and Mrs. B., the two MS patients described in the 
introduction of this thesis? First of all, assuming that underlying somatic causes for 
fatigue such as a urinal infection are excluded, both patients should be screened for 
depression. If Ms. A. and Mrs. B. appear to be clinically depressed, they should be 
treated by cognitive behavioural therapy [96] and/or anti-depressive medication [97, 
98]. Secondly, if both patients, after adequate treatment of their depression, still report 
disabling fatigue, both could benefit from cognitive behavioural interventions [84]. Such 
an intervention should start with a comprehensive clinical evaluation of fatigue, includ-
ing all possible influencing psychological variables, such as sleep disorder, pain, catas-
trophizing about fatigue, fatigue-related fear and avoidance behaviour. Also a neuro-
psychological assessment could be included while both patients experience cognitive 
complaints. Neuropsychological assessment, including the additional assessment of 
anxiety, depression and fatigue will be needed to clearly indicate whether their experi-
ence is due to cognitive dysfunctioning, or due to mood problems and fatigue [99, 100]. 
After that, both patients, and in case of Mrs. B. also her husband, should be informed 
that the way patients perceive and think about their fatigue could influence fatigue and 
physical disability. Negative thoughts about fatigue and physical activity should be de-
tected and adjusted and physical activity should be encouraged in general. Finally, both 
patients could benefit from energy conserving strategies to cope with their fatigue and 
to optimize the use of available energy by modifying their daily activities, incorporating 
rest and restarting activities [101-103]. These cognitive behavioural interventions 
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should be integrated in a multidisciplinary rehabilitation programme, including occupa-
tional therapy and physiotherapy to improve their overall quality of life [94, 104].  
Conclusion 
In the present thesis, we enhanced our knowledge and understanding of MS-related 
fatigue and provided insight into its psychological correlates. Of course, not all of the 
potential contributing factors to MS-related fatigue have been investigated in this the-
sis; and we acknowledge that biological factors can contribute to fatigue. Nevertheless, 
a psychological approach to the understanding and treatment of fatigue seems promis-
ing. Moreover, this conclusion is in line with the modern, integrated, approach in medi-
cine. It sends out a positive message that opens new ways to treatment options for MS 
patients who suffer from fatigue.  
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Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system and the most common neurological disorders affecting young adults. 
The clinical picture of MS is diverse, including both physical and neuropsychiatric symp-
toms. Fatigue is one of the most common and disabling symptoms of MS, but its aetiol-
ogy is still poorly understood and treatment options are limited. Fatigue cannot fully be 
explained by biological factors and a psychological approach may be helpful to further 
explain and treat fatigue in MS. Therefore, the general aim of this thesis was to better 
understand the concept of MS-related fatigue from a psychological perspective. As such 
the focus was on identifying relevant psychological factors in explaining MS-related 
fatigue and their added value to biological factors, such as disease severity and cerebral 
white matter lesions. More specifically, we studied the impact of fatigue on cognition, 
the disease specificity of MS-related fatigue, and the extent to which it can be explained 
by depression, negative affectivity, and cognitive behavioural factors.  
 
Chapter 1 is a general introduction into the clinical diagnosis of multiple sclerosis: its 
epidemiology, aetiology, pathophysiology and symptoms, including fatigue. Two case 
reports are presented to illustrate the clinical presentation of fatigue and its impact on 
daily life. Finally, the aim, the research questions, and the outline of this thesis are 
presented.  
 
Chapter 2 presents a critical review of the existing literature on MS-related fatigue and 
its psychological correlates. We started by defining fatigue in MS and discussed its 
measurement. Next, we focused on conceptual issues including the relationships be-
tween MS-related fatigue and mood, anxiety, and cognitive impairment, and the impact 
of both personality and cognitive behavioural factors on MS-related fatigue. Implica-
tions for clinical practice and research are presented.  
 
In Chapter 3 we investigated the contribution of physical and mental fatigue to both 
cognitive complaints and cognitive performance in 80 MS patients. A relatively exten-
sive neuropsychological assessment battery was used which included a number of tasks 
that required effortful information processing. Our study revealed that mental fatigue 
together with anxiety and depression accounted for a substantial part of the total vari-
ance of cognitive complaints. The contribution of physical fatigue to cognitive com-
plaints was not significant. Neither physical, nor mental fatigue was related to mental 
speed, attention, memory and executive functioning. To refine interventions for those 
patients with cognitive complaints, we advise adding measurements of anxiety, depres-
sion and fatigue to their neuropsychological assessment. Because fatigue in MS patients 
is not related to cognitive performance, it is permitted to use extensive neuropsy-
chological assessment in fatigued patients with MS. Given the impact of cognitive im-
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pairment on daily life, and its heterogeneity in MS, extensive neuropsychological as-
sessment is needed to detect even subtle cognitive dysfunction. 
 
In Chapter 4 we focused on mental fatigue in 40 MS patients and its disease specificity 
by comparing its levels and correlates with those of 19 healthy control participants (HC) 
and 20 patients with ulcerative colitis (UC), which is a non-neurological, chronic, and 
intermittent, auto-immune disease. To better understand MS-related mental fatigue, 
we used a subjective and objective measure of fatigue. Besides measurement by self-
report, mental fatigue was also measured by a decreased performance on a task that 
required sustained mental effort. We explored the associations between both (subjec-
tive and objective) measures of mental fatigue and disease severity in both patient 
samples. Next, the associations between both measures of mental fatigue on the one 
hand and both cerebral white matter lesion load measured by magnetic resonance 
imaging, and depressive complaints on the other hand, were investigated in all three 
groups. Our findings revealed that MS patients experienced more mental fatigue than 
both control groups, but the three groups did not differ with regard to the objective 
measurement of mental fatigue. The total amount of cerebral white matter leasion load 
and disease severity did not correlate with both measures of mental fatigue. Depressive 
complaints were only correlated with subjective assessment of mental fatigue in the HC 
group and not in the MS and UC sample. In conclusion, our distinction between subjec-
tive and objective assessment of mental fatigue did not help us to find an explanation in 
terms of either disease specificity or significant correlates of MS-related mental fatigue.  
 
In Chapter 5 we again examined the disease specificity of fatigue in MS. We compared 
MS patients with UC patients, but now we focused on the impact of disease severity, 
depression and negative affectivity on subjective measures of both physical and mental 
fatigue. A total of 88 MS and 76 UC patients were included in this cross-sectional study. 
While levels of both physical and mental fatigue were significantly higher in MS patients 
than in UC patients, there were no group differences in the contribution of disease 
severity, depression and negative affectivity to both physical and mental fatigue. Our 
study revealed that disease severity was an independent contributor to physical fatigue, 
but not to mental fatigue, while the opposite was the case for negative affectivity. De-
pression contributed to both physical and mental fatigue. Although levels of fatigue 
were higher for MS patients when compared with UC patients, their correlates do not 
indicate MS specificity. As such our results support a trans-diagnostic approach to fa-
tigue in MS.  
 
In Chapter 6 we investigated the role of catastrophic (mis)interpretations of fatigue on 
fatigue and physical disability in a sample of 262 MS patients. We compared a cognitive 
behavioural model with a traditional biomedical model using structural equation mod-
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elling (SEM). The explorative use of SEM resulted in an integrated cognitive behavioural 
model, in which catastrophizing about fatigue was a key factor that mediated the rela-
tionship between fatigue and fatigue-related fear and avoidance behaviour. Disease 
severity did indirectly contribute to fatigue, through fatigue-related fear and avoidance 
behaviour as well as physical disability. Depression appeared to be a negative conse-
quence of physical disability, and contributed directly to both fatigue as well as to 
catastrophizing about fatigue. Our study revealed that not just the severity of symp-
toms, but catastrophizing about fatigue, and fatigue-related fear and avoidance behav-
iour, in combination with depression, were significant determinants of fatigue and 
physical disability levels in MS patients. Our results suggest that the modification of 
catastrophic thoughts about fatigue may be a promising intervention method to help 
MS patients achieve their daily life goals.  
 
Finally, in Chapter 7, the main findings of this thesis are summarized, discussed, and 
placed into perspective within the context of this thesis and the recent literature. 
Methodological issues with regard to the studies conducted are discussed and recom-
mendations for future research and clinical practice are presented. By considering the 
methodological limitations of the studies we conducted, the present work has en-
hanced our knowledge and understanding of MS-related fatigue and provided insight 
into its psychological correlates. The findings of this thesis support the conclusion that a 
psychological approach of MS-related fatigue is promising and that this approach can 
be used for the development of new interventions to reduce fatigue and improve the 
quality of life of patients with MS.  
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Samenvatting 
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Multiple sclerose (MS) is een chronische inflammatoire demyeliniserende aandoening 
van het centrale zenuwstelsel en de meest voorkomende neurologische aandoening op 
jongvolwassen leeftijd. Het klinisch beeld van MS is divers en omvat zowel lichamelijke 
als neuropsychiatrische symptomen. Vermoeidheid is één van de meest voorkomende 
en hinderlijke symptomen van MS. De oorzaak van vermoeidheid is nog steeds onbe-
kend en de behandelingmogelijkheden zijn beperkt. Vermoeidheid bij MS kan niet ge-
heel door biologische factoren worden verklaard en derhalve zou een psychologische 
benadering kunnen bijdragen aan de verklaring en behandeling van vermoeidheid bij 
MS. De doelstelling van dit proefschrift was om het concept MS-gerelateerde ver-
moeidheid beter te begrijpen vanuit een psychologisch perspectief. We hebben ons 
gericht op de toegevoegde waarde van psychologische factoren naast biologische facto-
ren, zoals de ernst van de ziekte en cerebrale witte stofafwijkingen. We bestudeerden 
de invloed van vermoeidheid op cognitie, de ziektespecificiteit van MS-gerelateerde 
vermoeidheid en de mate waarin het verklaard kan worden door depressie, negatieve 
affectiviteit en cognitief gedragsmatige factoren.  
 
Hoofdstuk 1 betreft een algemene inleiding en beschrijft het ziektebeeld MS en MS-
gerelateerde vermoeidheid. Er worden twee casussen gepresenteerd om de klinische 
presentatie van vermoeidheid en de invloed op het dagelijkse leven te illustreren. Ten 
slotte worden de doelstelling, de onderzoeksvragen en de opbouw van dit proefschrift 
beschreven. 
 
In Hoofdstuk 2 wordt een kritisch overzicht gegeven van de bestaande literatuur over 
de bijdrage van psychologische factoren aan MS-gerelateerde vermoeidheid. Allereerst 
wordt aandacht besteed aan de definitie en het meten van vermoeidheid bij MS. Ver-
volgens hebben we ons gericht op conceptuele kwesties, namelijk de relatie tussen MS 
gerelateerde vermoeidheid enerzijds en stemming, angst en cognitief functioneren 
anderzijds. Daarnaast hebben we de invloed van persoonlijkheid en cognitief gedrags-
matige factoren op vermoeidheid bij MS in kaart gebracht. Ten slotte hebben we aan-
bevelingen gedaan voor de klinische praktijk en verder onderzoek. 
 
In Hoofdstuk 3 onderzochten we de invloed van lichamelijke en mentale vermoeidheid 
op zowel cognitieve klachten als cognitieve prestaties bij 80 patiënten met MS. Er werd 
een uitgebreide neuropsychologische testbatterij gebruikt met diverse taken die relatief 
veel mentale inspanning vereisen. De resultaten laten zien dat mentale vermoeidheid, 
samen met angst en depressie, een substantieel deel van cognitieve klachten verklaart.  
Lichamelijke vermoeidheid draagt niet bij aan cognitieve klachten. Voorts zijn zowel 
lichamelijke als mentale vermoeidheid niet gerelateerd aan de snelheid van informatie-
verwerking, aandacht, geheugen en executief functioneren. We adviseren om het neu-
ropsychologisch onderzoek bij MS patiënten uit te breiden met onderzoek van angst,  
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depressie en vermoeidheid gegeven hun invloed op cognitieve klachten. Omdat ver-
moeidheid bij MS patiënten niet gerelateerd is aan cognitieve prestaties, is uitgebreid 
neuropsychologisch onderzoek bij vermoeide MS patiënten gerechtvaardigd. Juist van-
wege het voorkomen van relatief subtiele cognitieve tekorten bij MS en de impact 
hiervan op het dagelijks functioneren, is uitgebreid neuropsychologisch onderzoek 
noodzakelijk om cognitieve tekorten te kunnen objectiveren. 
 
In Hoofdstuk 4 hebben we ons gericht op mentale vermoeidheid bij MS en de ziekte-
specificiteit hiervan. We hebben 40 MS patiënten vergeleken met 19 gezonde controle 
proefpersonen en 20 patiënten met colitis ulcerosa (CU), een niet-neurologische, chro-
nische en intermitterende auto-immuunziekte. Mentale vermoeidheid werd niet alleen 
gemeten met een zelfrapportagevragenlijst (subjectieve mentale vermoeidheid), maar 
ook middels een taak die volgehouden mentale inspanning vergt (objectieve mentale 
vermoeidheid). In beide patiëntenpopulaties exploreerden we de relaties tussen de 
mate van subjectief en objectief gemeten vermoeidheid en de ernst van de ziekte. 
Vervolgens hebben we in de drie verschillende groepen de relaties onderzocht tussen 
enerzijds de subjectieve en objectieve maat van mentale vermoeidheid en anderzijds 
cerebrale witte stof laesies gemeten middels magnetische resonantie imaging en de-
pressieve klachten. Onze bevindingen laten zien dat MS patiënten meer mentale ver-
moeidheid ervaren dan beide controlegroepen, maar dat de drie groepen niet verschi-
len wat betreft de objectieve maat van mentale vermoeidheid. De ernst van de ziekte 
en de totale hoeveelheid cerebrale witte stof laesies hangen niet samen met beide 
maten van mentale vermoeidheid. Depressieve klachten correleren alleen in de groep 
gezonde controle proefpersonen met de subjectieve maat van mentale vermoeidheid. 
Concluderend heeft het onderscheid tussen subjectief en objectief gemeten mentale 
vermoeidheid niet bij kunnen dragen aan ons inzicht in het wel of niet ziektespecifiek 
zijn van mentale vermoeidheid bij MS.  
 
In Hoofdstuk 5 onderzochten we wederom de ziektespecificiteit van vermoeidheid bij 
MS door 88 MS patiënten te vergelijken met 76 CU patiënten. We hebben ons gericht 
op de bijdrage van ziekte-ernst, depressie en negatieve affectiviteit aan zowel lichame-
lijke als mentale vermoeidheid. Hoewel MS patiënten zowel meer lichamelijke als men-
tale vermoeidheid ervaren dan CU patiënten, vonden we geen groepsverschillen ten 
aanzien van de bijdrage van ziekte-ernst, depressie en negatieve affectiviteit aan zowel 
lichamelijke als mentale vermoeidheid. Deze studie laat zien dat ziekte-ernst een onaf-
hankelijke bijdrage levert aan lichamelijke vermoeidheid en niet aan mentale ver-
moeidheid, terwijl het tegenovergestelde het geval is voor negatieve affectiviteit. De-
pressie levert zowel een bijdrage aan lichamelijke als aan mentale vermoeidheid. Hoe-
wel MS patiënten meer vermoeidheid ervaren dan CU patiënten, zijn de correlaten niet 
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specifiek voor MS en ondersteunen de resultaten een transdiagnostische benadering 
van vermoeidheid bij MS.  
 
In Hoofdstuk 6 hebben we de invloed van catastrofale (mis)interpretaties op vermoeid-
heid en lichamelijke beperkingen onderzocht in een groep van 262 MS patiënten. We 
hebben een cognitief gedragsmatig model vergeleken met een traditioneel biomedisch 
model middels structural equation modeling. Exploratief gebruik van deze methode 
heeft ons geleid naar een geïntegreerd cognitief gedragsmatig model, waarin catastro-
feren over vermoeidheid een sleutelrol vervult en de relatie tussen vermoeidheid en 
vermoeidheid gerelateerde angst en vermijdingsgedrag medieert. In dit geïntegreerde 
model draagt ziekte-ernst indirect bij aan vermoeidheid, via zowel vermoeidheid gere-
lateerde angst en vermijdingsgedrag als lichamelijke beperkingen. Depressie blijkt een 
negatief gevolg te zijn van lichamelijke beperkingen en draagt direct bij aan zowel ver-
moeidheid als catastroferen over vermoeidheid. Onze studie laat zien dat niet alleen de 
ernst van de symptomen, maar met name catastroferen over vermoeidheid, vermoeid-
heid gerelateerde angst en vermijding, in combinatie met depressie, significante deter-
minanten zijn van vermoeidheid en lichamelijke beperkingen bij MS patiënten. De resul-
taten suggereren dat modificatie van catastroferende gedachten over vermoeidheid 
een veelbelovende interventiemethode kan zijn om ervoor te zorgen dat MS patiënten 
hun doelen in het dagelijkse leven kunnen bereiken.  
 
Ten slotte worden in Hoofdstuk 7 de belangrijkste bevindingen van dit proefschrift 
samengevat, bediscussieerd en in het perspectief van de context van dit proefschrift en 
de recente literatuur geplaatst. Tevens worden hier methodologische aspecten bedis-
cussieerd en aanbevelingen beschreven voor toekomstig onderzoek en de klinische 
praktijk. Rekening houdend met de methodologische beperkingen, heeft het huidige 
proefschrift onze kennis en begrip van MS-gerelateerde vermoeidheid vergroot en 
inzicht verschaft in de relatie met psychologische variabelen. De bevindingen van dit 
proefschrift ondersteunen de conclusie dat een psychologische benadering van MS-
gerelateerde vermoeidheid veelbelovend is en dat deze gebruikt kan worden om inter-
venties te ontwikkelen ten einde vermoeidheid te verminderen en de kwaliteit van 
leven van MS patiënten te verbeteren.   
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der noemen.  
 
Allereerst wil ik alle personen die hebben meegedaan aan het onderzoek bedanken 
voor hun medewerking. Zonder uw bereidheid en inzet was dit proefschrift er nooit 
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De leden van de leescommissie en de corona bedank ik voor het lezen en beoordelen 
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afgelopen jaren heeft begeleid. Het was voor mij soms best lastig om naast alle klini-
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proefschrift te schrijven. Promotieteam, bedankt voor het vertrouwen, jullie input en 
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werking in de toekomst zullen voortzetten.  
 
Speciale dank gaat uit naar Christianne Vertommen-Mertens. Beste Christianne, jij was 
vanaf het begin bij het onderzoek betrokken en met veel enthousiasme en inzet heb jij 
een belangrijke bijdrage geleverd aan de dataverzameling. Je was niet alleen als psy-
chodiagnostisch medewerker bij het onderzoek betrokken, maar ook als stagiaire tij-
dens je afstudeerstage voor GGK. Bedankt voor al jouw hulp! 
 
Verder wil ik alle anderen die sinds 2004 direct of indirect als stagiaire, APNIO of onder-
zoeksassistent een bijdrage hebben geleverd aan het onderzoek bedanken: Inge Verlin-
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en het invoeren en controleren van data. Ook werd ik ontlast doordat een aantal van 
jullie zowel klinische als onderwijstaken van mij overnamen. Bedankt!  
 
Alle (oud)-collega’s van het MS-team van het MUMC, bedankt voor de samenwerking 
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Prof. dr. R.J. Brummer, bedankt voor uw bijdrage bij de start van het onderzoek en het 
zoeken naar een goede controlegroep. Alle andere collega’s van de afdeling interne 
geneeskunde van het MUMC, in het bijzonder Mariëlle Romberg-Camps en Martine 
Hesselink-van de Kruijs, bedankt voor de prettige manier waarop we hebben samen 
gewerkt. Beste Mariëlle, leuk dat we nu weer collega’s zijn. Succes met jouw laatste 
loodjes! 
 
Collega’s van de afdeling Radiologie van het MUMC, hartelijk bedankt voor alle hulp. 
Frans Bakers, bedankt voor de tijd en energie die je hebt gestoken in het beoordelen 
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logistieke ondersteuning hierbij.  
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